{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T07:00:23Z","timestamp":1792220423222,"version":"4.4.0"},"reference-count":193,"publisher":"S.C. JURNALUL PENTRU MEDICINA SI VIATA S.R.L","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMedLife"],"DOI":"10.25122\/jml-2023-0404","type":"journal-article","created":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T06:13:35Z","timestamp":1724048015000},"page":"246-260","source":"Crossref","is-referenced-by-count":37,"title":["The burden of antibiotic resistance of the main microorganisms causing infections in humans \u2013 review of the literature"],"prefix":"10.25122","volume":"17","author":[{"given":"Alexandru-Paul","family":"Baciu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"MedLife Hyperclinic Nicolae Balcescu, Galati, Romania","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Baciu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"MedLife Hyperclinic Nicolae Balcescu, Galati, Romania","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginel","family":"Baciu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Sf. Ioan Emergency Clinical Hospital for Children, Galati, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Faculty of Medicine and Pharmacy, Dunarea de Jos University, Galati, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Gurau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Sf. Ioan Emergency Clinical Hospital for Children, Galati, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Faculty of Medicine and Pharmacy, Dunarea de Jos University, Galati, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10755","published-online":{"date-parts":[[2024,3]]},"reference":[{"issue":"10325","key":"ref1","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","unstructured":"1. Antimicrobial Resistance Collaborators, Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis, Lancet, 2022;399(10325):629-655","journal-title":"Lancet"},{"key":"ref2","article-title":"Antimicrobial Resistance","author":"World Health Organization","unstructured":"2. World Health Organization, Antimicrobial Resistance, Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/antimicrobial-resistance"},{"issue":"8","key":"ref3","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.3390\/antibiotics11081082","article-title":"Antimicrobial Resistance and Its Spread Is a Global Threat","volume":"11","author":"Aljeldah MM","year":"2022","unstructured":"3. Aljeldah MM, Antimicrobial Resistance and Its Spread Is a Global Threat, Antibiotics (Basel), 2022;11(8):1082","journal-title":"Antibiotics (Basel)"},{"issue":"8","key":"ref4","first-page":"516","article-title":"Urinary tract infection with Candida glabrata in a patient with spinal cord injury","volume":"53","author":"Rahimkhani M, Saberian M, Mordadi A","year":"2015","unstructured":"4. Rahimkhani M, Saberian M, Mordadi A, Urinary tract infection with Candida glabrata in a patient with spinal cord injury, Acta Medica Iranica, 2015;53(8):516-517","journal-title":"Acta Medica Iranica"},{"issue":"2","key":"ref5","first-page":"178","article-title":"Urinary tract infection in spinal cord injuries","volume":"7","author":"Rahimkhani M, Nikfalah A, Saberian M, Mordadi A, Varmazyar S, Tavakoli A","year":"2014","unstructured":"5. Rahimkhani M, Nikfalah A, Saberian M, Mordadi A, Varmazyar S, Tavakoli A, Urinary tract infection in spinal cord injuries, Asian Journal of Pharmaceutical and Clinical Research, 2014;7(2):178-182","journal-title":"Asian Journal of Pharmaceutical and Clinical Research"},{"key":"ref6","article-title":"Antibiotic re-sistance threats in the United States","author":"Centers for Disease Control and Prevention Office of Infectious Disease","year":"2013","unstructured":"6. Centers for Disease Control and Prevention Office of Infectious Disease, Antibiotic re-sistance threats in the United States, 2013;Available from: http:\/\/www.cdc.gov\/drugresistance\/threat-report-2013"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.coph.2014.09.006","article-title":"Update on the antibiotic resistance crisis","volume":"18","author":"Rossolini GM, Arena F, Pecile P, Pollini S","year":"2014","unstructured":"7. Rossolini GM, Arena F, Pecile P, Pollini S, Update on the antibiotic resistance crisis, Curr Opin Pharmacol, 2014;1856-60","journal-title":"Curr Opin Pharmacol"},{"issue":"2","key":"ref8","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3855\/jidc.3573","article-title":"Bacteriophage therapy: a potential solution for the antibiotic resistance crisis","volume":"8","author":"Golkar Z, Bagasra O, Pace DG","year":"2014","unstructured":"8. Golkar Z, Bagasra O, Pace DG, Bacteriophage therapy: a potential solution for the antibiotic resistance crisis, J Infect Dev Ctries, 2014;8(2):129-36","journal-title":"J Infect Dev Ctries"},{"issue":"24","key":"ref9","doi-asserted-by":"publisher","first-page":"R1063","DOI":"10.1016\/j.cub.2013.11.057","article-title":"Antibiotics in crisis","volume":"23","author":"Gross M","year":"2013","unstructured":"9. Gross M, Antibiotics in crisis, Curr Biol, 2013;23(24):R1063-5","journal-title":"Curr Biol"},{"issue":"9","key":"ref10","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1056\/NEJMoa1405870","article-title":"Community-acquired pneumonia requiring hospitalization among US children","volume":"372","author":"Jain S, Williams DJ, Arnold SR, Ampofo K, Bramley AM, Reed C","year":"2015","unstructured":"10. Jain S, Williams DJ, Arnold SR, Ampofo K, Bramley AM, Reed C, Community-acquired pneumonia requiring hospitalization among US children, N Engl J Med, 2015;372(9):835-845","journal-title":"N Engl J Med"},{"issue":"9","key":"ref11","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1097\/00006454-200209000-00005","article-title":"Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia","volume":"21","author":"Black SB, Shinefield HR, Ling S, Hansen J, Fireman B, Spring D","year":"2002","unstructured":"11. Black SB, Shinefield HR, Ling S, Hansen J, Fireman B, Spring D, Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia, Pediatr Infect Dis J, 2002;21(9):810-5","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"ref12","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1097\/01.inf.0000202137.37642.ab","article-title":"Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema","volume":"25","author":"Byington CL, Korgenski K, Daly J, Ampofo K, Pavia A, Mason EO","year":"2006","unstructured":"12. Byington CL, Korgenski K, Daly J, Ampofo K, Pavia A, Mason EO, Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema, Pediatr Infect Dis J, 2006;25(3):250-4","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"ref13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1542\/peds.2009-0184","article-title":"Empyema hospitalizations increased in US children despite pneumococcal conjugate vaccine","volume":"125","author":"Li ST, Tancredi DJ","year":"2010","unstructured":"13. Li ST, Tancredi DJ, Empyema hospitalizations increased in US children despite pneumococcal conjugate vaccine, Pediatrics, 2010;125(1):26-33","journal-title":"Pediatrics"},{"issue":"4","key":"ref14","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1086\/338460","article-title":"An epidemiological investigation of a sustained high rate of pediatric parapneumonic empyema: risk factors and microbiological associations","volume":"34","author":"Byington CL, Spencer LY, Johnson TA, Pavia AT, Allen D, Mason EO","year":"2002","unstructured":"14. Byington CL, Spencer LY, Johnson TA, Pavia AT, Allen D, Mason EO, An epidemiological investigation of a sustained high rate of pediatric parapneumonic empyema: risk factors and microbiological associations, Clin Infect Dis, 2002;34(4):434-40","journal-title":"Clin Infect Dis"},{"issue":"12","key":"ref15","doi-asserted-by":"publisher","first-page":"e320","DOI":"10.1097\/INF.0000000000002474","article-title":"Increasing Rates of Pediatric Empyema and Disease Severity With Predominance of Serotype 3 S. pneumonia: An Australian Single-center. Retrospective Cohort 2011 to 2018","volume":"38","author":"Haggie S, Fitzgerald DA, Pandit C, Selvadurai H, Robinson P, Gunasekera H","year":"2019","unstructured":"15. Haggie S, Fitzgerald DA, Pandit C, Selvadurai H, Robinson P, Gunasekera H, Increasing Rates of Pediatric Empyema and Disease Severity With Predominance of Serotype 3 S. pneumonia: An Australian Single-center. Retrospective Cohort 2011 to 2018, Pediatr Infect Dis J, 2019;38(12):e320-e325","journal-title":"Pediatr Infect Dis J"},{"issue":"7","key":"ref16","first-page":"152","article-title":"Effect of new susceptibility breakpoints on reporting of resistance in Streptococcus pneumoniae--United States, 2003","volume":"53","author":"Centers for Disease Control and Prevention (CDC)","year":"2004","unstructured":"16. Centers for Disease Control and Prevention (CDC), Effect of new susceptibility breakpoints on reporting of resistance in Streptococcus pneumoniae--United States, 2003, MMWR Morb Mortal Wkly Rep, 2004;53(7):152-154","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"50","key":"ref17","first-page":"1353","article-title":"Effects of new penicillin susceptibility breakpoints for Streptococcus pneumoniae--United States, 2006-2007","volume":"57","author":"Centers for Disease Control and Prevention (CDC)","year":"2008","unstructured":"17. Centers for Disease Control and Prevention (CDC), Effects of new penicillin susceptibility breakpoints for Streptococcus pneumoniae--United States, 2006-2007, MMWR Morb Mortal Wkly Rep, 2008;57(50):1353-1355","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"ref18","doi-asserted-by":"publisher","first-page":"60e9","DOI":"10.1016\/j.cmi.2015.08.027","article-title":"Strain features and distributions in pneumococci from children with invasive disease before and after 13-valent conjugate vaccine implementation in the USA","volume":"22","author":"Metcalf BJ, Gertz RE, Gladstone RA, Walker H, Sherwood LK, Jackson D, Active Bacterial Core surveillance team","year":"2016","unstructured":"18. Metcalf BJ, Gertz RE, Gladstone RA, Walker H, Sherwood LK, Jackson D, Active Bacterial Core surveillance team, Strain features and distributions in pneumococci from children with invasive disease before and after 13-valent conjugate vaccine implementation in the USA, Clin Microbiol Infect, 2016;22(1):60e9-60.e29","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"ref19","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1093\/cid\/cix446","article-title":"A Population-Based Assessment of the Impact of 7-and 13-Valent Pneumococcal Conjugate Vaccines on Macrolide-Resistant Invasive Pneumococcal Disease: Emergence and Decline of Streptococcus pneumoniae Serotype 19A (CC320) With Dual Macrolide Resistance Mechanisms","volume":"65","author":"Schroeder MR, Chancey ST, Thomas S, Kuo WH, Satola SW, Farley MM, Stephens DS","year":"2017","unstructured":"19. Schroeder MR, Chancey ST, Thomas S, Kuo WH, Satola SW, Farley MM, Stephens DS, A Population-Based Assessment of the Impact of 7-and 13-Valent Pneumococcal Conjugate Vaccines on Macrolide-Resistant Invasive Pneumococcal Disease: Emergence and Decline of Streptococcus pneumoniae Serotype 19A (CC320) With Dual Macrolide Resistance Mechanisms, Clin Infect Dis, 2017;65(6):990-998","journal-title":"Clin Infect Dis"},{"issue":"3","key":"ref20","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1128\/CMR.00058-15","article-title":"Biological and Epidemiological Features of Antibiotic-Resistant Streptococcus pneumoniae in Pre-and Post-Conjugate Vaccine Eras: a United States Perspective","volume":"29","author":"Kim L, McGee L, Tomczyk S, Beall B","year":"2016","unstructured":"20. Kim L, McGee L, Tomczyk S, Beall B, Biological and Epidemiological Features of Antibiotic-Resistant Streptococcus pneumoniae in Pre-and Post-Conjugate Vaccine Eras: a United States Perspective, Clin Microbiol Rev, 2016;29(3):525-52","journal-title":"Clin Microbiol Rev"},{"issue":"7","key":"ref21","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.jiac.2020.02.013","article-title":"Two cases of bacterial meningitis due to meropenem-resistant Streptococcus pneumoniae: A threat of serotype 35B, ST 558 lineage","volume":"26","author":"Yamada N, Nakamoto T, Takei H, Shoji T, Takahashi K, Sato J","year":"2020","unstructured":"21. Yamada N, Nakamoto T, Takei H, Shoji T, Takahashi K, Sato J, Two cases of bacterial meningitis due to meropenem-resistant Streptococcus pneumoniae: A threat of serotype 35B, ST 558 lineage, J Infect Chemother, 2020;26(7):745-748","journal-title":"J Infect Chemother"},{"issue":"9","key":"ref22","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1093\/cid\/ciw067","article-title":"Prevention of Antibiotic-Nonsusceptible Invasive Pneumococcal Disease With the 13-Valent Pneumococcal Conjugate Vaccine","volume":"62","author":"Tomczyk S, Lynfield R, Schaffner W, Reingold A, Miller L, Petit S","year":"2016","unstructured":"22. Tomczyk S, Lynfield R, Schaffner W, Reingold A, Miller L, Petit S, Prevention of Antibiotic-Nonsusceptible Invasive Pneumococcal Disease With the 13-Valent Pneumococcal Conjugate Vaccine, Clin Infect Dis, 2016;62(9):1119-25","journal-title":"Clin Infect Dis"},{"issue":"8","key":"ref23","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1056\/NEJM199508243330803","article-title":"The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta","volume":"333","author":"Hofmann J, Cetron MS, Farley MM, Baughman WS, Facklam RR, Elliott JA","year":"1995","unstructured":"23. Hofmann J, Cetron MS, Farley MM, Baughman WS, Facklam RR, Elliott JA, The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta, N Engl J Med, 1995;333(8):481-6","journal-title":"N Engl J Med"},{"issue":"6","key":"ref24","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/s0022-3476(96)70326-8","article-title":"Risk factors for carriage of drug-resistant Streptococcus pneumoniae among children in Memphis, Tennessee","volume":"128","author":"Arnold KE, Leggiadro RJ, Breiman RF, Lipman HB, Schwartz B, Appleton MA","year":"1996","unstructured":"24. Arnold KE, Leggiadro RJ, Breiman RF, Lipman HB, Schwartz B, Appleton MA, Risk factors for carriage of drug-resistant Streptococcus pneumoniae among children in Memphis, Tennessee, J Pediatr, 1996;128(6):757-64","journal-title":"J Pediatr"},{"issue":"12","key":"ref25","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1097\/00006454-200012000-00011","article-title":"Frequency of penicillin-resistant pneumococci in children is correlated to community utilization of antibiotics","volume":"19","author":"Melander E, Ekdahl K, J\u00f6nsson G, M\u00f6lstad S","year":"2000","unstructured":"25. Melander E, Ekdahl K, J\u00f6nsson G, M\u00f6lstad S, Frequency of penicillin-resistant pneumococci in children is correlated to community utilization of antibiotics, Pediatr Infect Dis J, 2000;19(12):1172-7","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"ref26","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1086\/650496","article-title":"Increased penicillin nonsusceptibility of nonvaccine-serotype invasive pneumococci other than serotypes 19A and 6A in post-7-valent conjugate vaccine era","volume":"201","author":"Gertz RE, Li Z, Pimenta FC, Jackson D, Juni BA, Lynfield R, Active Bacterial Core Surveillance Team","year":"2010","unstructured":"26. Gertz RE, Li Z, Pimenta FC, Jackson D, Juni BA, Lynfield R, Active Bacterial Core Surveillance Team, Increased penicillin nonsusceptibility of nonvaccine-serotype invasive pneumococci other than serotypes 19A and 6A in post-7-valent conjugate vaccine era, J Infect Dis, 2010;201(5):770-5","journal-title":"J Infect Dis"},{"issue":"7","key":"ref27","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1093\/infdis\/jiu576","article-title":"Efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) versus that of 7-valent PCV (PCV7) against nasopharyngeal colonization of antibiotic-nonsusceptible Streptococcus pneumoniae","volume":"211","author":"Dagan R, Juergens C, Trammel J, Patterson S, Greenberg D, Givon-Lavi N","year":"2015","unstructured":"27. Dagan R, Juergens C, Trammel J, Patterson S, Greenberg D, Givon-Lavi N, Efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) versus that of 7-valent PCV (PCV7) against nasopharyngeal colonization of antibiotic-nonsusceptible Streptococcus pneumoniae, J Infect Dis, 2015;211(7):1144-53","journal-title":"J Infect Dis"},{"issue":"1","key":"ref28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/jpids\/pit057","article-title":"Impact of 13-Valent Pneumococcal Conjugate Vaccination on Streptococcus pneumoniae Carriage in Young Children in Massachusetts","volume":"3","author":"Lee GM, Kleinman K, Pelton SI, Hanage W, Huang SS, Lakoma M","year":"2014","unstructured":"28. Lee GM, Kleinman K, Pelton SI, Hanage W, Huang SS, Lakoma M, Impact of 13-Valent Pneumococcal Conjugate Vaccination on Streptococcus pneumoniae Carriage in Young Children in Massachusetts, J Pediatric Infect Dis Soc, 2014;3(1):23-32","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"5","key":"ref29","doi-asserted-by":"publisher","first-page":"e20170001","DOI":"10.1542\/peds.2017-0001","article-title":"Immunization, Antibiotic Use, and Pneumococcal Colonization Over a 15-Year Period","volume":"140","author":"Lee GM, Kleinman K, Pelton S, Lipsitch M, Huang SS, Lakoma M","year":"2017","unstructured":"29. Lee GM, Kleinman K, Pelton S, Lipsitch M, Huang SS, Lakoma M, Immunization, Antibiotic Use, and Pneumococcal Colonization Over a 15-Year Period, Pediatrics, 2017;140(5):e20170001","journal-title":"Pediatrics"},{"issue":"11","key":"ref30","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S1473-3099(05)70267-X","article-title":"The global burden of group A streptococcal diseases","volume":"5","author":"Carapetis JR, Steer AC, Mulholland EK, Weber M","year":"2005","unstructured":"30. Carapetis JR, Steer AC, Mulholland EK, Weber M, The global burden of group A streptococcal diseases, Lancet Infect Dis, 2005;5(11):685-94","journal-title":"Lancet Infect Dis"},{"issue":"Pt 1","key":"ref31","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1099\/mic.0.021048-0","article-title":"Biofilm formation by group A Streptococcus: a role for the streptococcal regulator of virulence (Srv) and streptococcal cysteine protease (SpeB)","volume":"155","author":"Doern CD, Roberts AL, Hong W, Nelson J, Lukomski S, Swords WE","year":"2009","unstructured":"31. Doern CD, Roberts AL, Hong W, Nelson J, Lukomski S, Swords WE, Biofilm formation by group A Streptococcus: a role for the streptococcal regulator of virulence (Srv) and streptococcal cysteine protease (SpeB), Microbiology (Reading), 2009;155(Pt 1):46-52","journal-title":"Microbiology (Reading)"},{"issue":"4","key":"ref32","doi-asserted-by":"publisher","first-page":"GPP3","DOI":"10.1128\/microbiolspec.GPP3-0049-2018","article-title":"Intracellular Invasion by Streptococcus pyogenes: Invasins, host re-ceptors, and relevance to human disease","volume":"7","author":"Wang B, Cleary PP","year":"2018","unstructured":"32. Wang B, Cleary PP, Intracellular Invasion by Streptococcus pyogenes: Invasins, host re-ceptors, and relevance to human disease, Microbiol Spectrum, 2018;7(4):GPP3-0049","journal-title":"Microbiol Spectrum"},{"issue":"1","key":"ref33","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1093\/cid\/ciz1000","article-title":"Streptococcus pyogenes pbp2x Mutation Confers Reduced Susceptibility to \u03b2-Lactam Antibiotics","volume":"71","author":"Vannice KS, Ricaldi J, Nanduri S, Fang FC, Lynch JB, Bryson-Cahn C","year":"2020","unstructured":"33. Vannice KS, Ricaldi J, Nanduri S, Fang FC, Lynch JB, Bryson-Cahn C, Streptococcus pyogenes pbp2x Mutation Confers Reduced Susceptibility to \u03b2-Lactam Antibiotics, Clin Infect Dis, 2020;71(1):201-204","journal-title":"Clin Infect Dis"},{"issue":"4","key":"ref34","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1542\/peds.113.4.866","article-title":"Meta-analysis of cephalosporin versus penicillin treatment of group A streptococcal tonsillopharyngitis in children","volume":"113","author":"Casey JR, Pichichero ME","year":"2004","unstructured":"34. Casey JR, Pichichero ME, Meta-analysis of cephalosporin versus penicillin treatment of group A streptococcal tonsillopharyngitis in children, Pediatrics, 2004;113(4):866-82","journal-title":"Pediatrics"},{"issue":"5","key":"ref35","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1542\/peds.2004-0133","article-title":"Group A streptococci among school-aged children: clinical characteristics and the carrier state","volume":"114","author":"Martin JM, Green M, Barbadora KA, Wald ER","year":"2004","unstructured":"35. Martin JM, Green M, Barbadora KA, Wald ER, Group A streptococci among school-aged children: clinical characteristics and the carrier state, Pediatrics, 2004;114(5):1212-9","journal-title":"Pediatrics"},{"issue":"4 Pt 1","key":"ref36","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1542\/peds.104.4.911","article-title":"Potential mechanisms for failure to eradicate group A streptococci from the pharynx","volume":"104","author":"Gerber MA, Tanz RR, Kabat W, Bell GL, Siddiqui Bp, Lerer TJ","year":"1999","unstructured":"36. Gerber MA, Tanz RR, Kabat W, Bell GL, Siddiqui Bp, Lerer TJ, Potential mechanisms for failure to eradicate group A streptococci from the pharynx, Pediatrics, 1999;104(4 Pt 1):911-7","journal-title":"Pediatrics"},{"issue":"5","key":"ref37","first-page":"88","article-title":"Outbreaks of community-associated methicillin-resistant Staphylococcus aureus skin infections--Los Angeles County, California, 2002-2003","volume":"52","author":"Centers for Disease Control and Prevention (CDC)","year":"2003","unstructured":"37. Centers for Disease Control and Prevention (CDC), Outbreaks of community-associated methicillin-resistant Staphylococcus aureus skin infections--Los Angeles County, California, 2002-2003, MMWR Morb Mortal Wkly Rep, 2003;52(5):88","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"S344","DOI":"10.1086\/533590","article-title":"Epidemiology of methicillin-resistant Staphylococcus aureus","volume":"46","author":"Boucher HW, Corey GR","year":"2008","unstructured":"38. Boucher HW, Corey GR, Epidemiology of methicillin-resistant Staphylococcus aureus, Clin Infect Dis, 2008;46(Suppl 5):S344-9","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2(Suppl 2)","key":"ref39","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1093\/cid\/ciu392","article-title":"The future of antibiotics and resistance: a tribute to a career of leadership by John Bartlett","volume":"59","author":"Spellberg B, Gilbert DN","year":"2014","unstructured":"39. Spellberg B, Gilbert DN, The future of antibiotics and resistance: a tribute to a career of leadership by John Bartlett, Clin Infect Dis, 2014;59(Suppl 2(Suppl 2)):S71-5","journal-title":"Clin Infect Dis"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3389\/fmicb.2013.00047","article-title":"The multifaceted roles of antibiotics and antibiotic resistance in nature","volume":"4","author":"Sengupta S, Chattopadhyay MK, Grossart HP","year":"2013","unstructured":"40. Sengupta S, Chattopadhyay MK, Grossart HP, The multifaceted roles of antibiotics and antibiotic resistance in nature, Front Microbiol, 2013;447","journal-title":"Front Microbiol"},{"issue":"3","key":"ref41","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1128\/CMR.00134-14","article-title":"Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management","volume":"28","author":"Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler VG","year":"2015","unstructured":"41. Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler VG, Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management, Clin Microbiol Rev, 2015;28(3):603-61","journal-title":"Clin Microbiol Rev"},{"issue":"6","key":"ref42","first-page":"578","article-title":"Survey of the Lethal Effect of Ciprofloxacin and Supernatant Isolated from Staphylococcus Aureus under the Stress of Ciprofloxacin on Methicillin-Resistant Staphylococcus Aureus Strains Isolated from Clinical Specimens","volume":"15","author":"Rahimkhani M, Mordadi AR","year":"2022","unstructured":"42. Rahimkhani M, Mordadi AR, Survey of the Lethal Effect of Ciprofloxacin and Supernatant Isolated from Staphylococcus Aureus under the Stress of Ciprofloxacin on Methicillin-Resistant Staphylococcus Aureus Strains Isolated from Clinical Specimens, Journal of Payavard Salamat, 2022;15(6):578-584","journal-title":"Journal of Payavard Salamat"},{"issue":"1","key":"ref43","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/00006454-198601000-00003","article-title":"Vaccine prevention of Haemophilus influenzae type b disease: past, present and future","volume":"5","author":"Cochi SL, Broome CV","year":"1986","unstructured":"43. Cochi SL, Broome CV, Vaccine prevention of Haemophilus influenzae type b disease: past, present and future, Pediatr Infect Dis, 1986;5(1):12-9","journal-title":"Pediatr Infect Dis"},{"key":"ref44","article-title":"Haemophilus Influenzae Disease (Including Hib)","author":"Centers for Disease Control and Prevention (CDC)","year":"2014","unstructured":"44. Centers for Disease Control and Prevention (CDC), Haemophilus Influenzae Disease (Including Hib), 2014;Available from: http:\/\/www.cdc.gov\/hi-disease"},{"issue":"2","key":"ref45","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/s0031-3955(05)70210-8","article-title":"Update on Haemophilus influenzae serotype b and meningococcal vaccines","volume":"47","author":"Rosenstein NE, Perkins BA","year":"2000","unstructured":"45. Rosenstein NE, Perkins BA, Update on Haemophilus influenzae serotype b and meningococcal vaccines, Pediatr Clin North Am, 2000;47(2):337-52vi","journal-title":"Pediatr Clin North Am"},{"key":"ref46","first-page":"234","article-title":"Progress toward elimination of Haemophilus influenzae type b invasive disease among infants and children--United States, 1998\u22122000","author":"Centers for Disease Control and Prevention (CDC)","year":"2002","unstructured":"46. Centers for Disease Control and Prevention (CDC), Progress toward elimination of Haemophilus influenzae type b invasive disease among infants and children--United States, 1998\u22122000, Morb Mortal Wkly Rep, 2002;234-237","journal-title":"Morb Mortal Wkly Rep"},{"issue":"7","key":"ref47","doi-asserted-by":"publisher","first-page":"e744","DOI":"10.1016\/S2214-109X(18)30247-X","article-title":"Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15","volume":"6","author":"Wahl B, O\u2019Brien KL, Greenbaum A, Majumder A, Liu L, Chu Y","year":"2018","unstructured":"47. Wahl B, O\u2019Brien KL, Greenbaum A, Majumder A, Liu L, Chu Y, Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15, Lancet Glob Health, 2018;6(7):e744-e757","journal-title":"Lancet Glob Health"},{"issue":"2","key":"ref48","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1128\/CMR.13.2.302","article-title":"Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates","volume":"13","author":"Peltola H","year":"2000","unstructured":"48. Peltola H, Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates, Clin Microbiol Rev, 2000;13(2):302-17","journal-title":"Clin Microbiol Rev"},{"key":"ref49","article-title":"Haemophilus influenzae type B","author":"World Health Organization","unstructured":"49. World Health Organization, Haemophilus influenzae type B, Available from: http:\/\/www.emro.who.int\/health-topics\/haemophilus-influenzae-type-b\/disease-burden.html"},{"issue":"12","key":"ref50","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/S1473-3099(14)70734-0","article-title":"Non-typeable Haemophilus influenzae, an under-recognised pathogen","volume":"14","author":"Van Eldere J, Slack MP, Ladhani S, Cripps AW","year":"2014","unstructured":"50. Van Eldere J, Slack MP, Ladhani S, Cripps AW, Non-typeable Haemophilus influenzae, an under-recognised pathogen, Lancet Infect Dis, 2014;14(12):1281-92","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"ref51","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1053\/srin.2000.0150041","article-title":"Haemophilus influenzae in chronic bronchitis","volume":"15","author":"Murphy TF","year":"2000","unstructured":"51. Murphy TF, Haemophilus influenzae in chronic bronchitis, Semin Respir Infect, 2000;15(1):41-51","journal-title":"Semin Respir Infect"},{"issue":"2","key":"ref52","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1128\/JCM.42.2.524-529.2004","article-title":"Analysis of invasive Haemophilus influenzae infections after extensive vaccination against H. influenzae type b","volume":"42","author":"Campos J, Hernando M, Rom\u00e1n F, P\u00e9rez-V\u00e1zquez M, Aracil B, Oteo J, Group of Invasive Haemophilus Infections of the Autonomous Community of Madrid, Spain","year":"2004","unstructured":"52. Campos J, Hernando M, Rom\u00e1n F, P\u00e9rez-V\u00e1zquez M, Aracil B, Oteo J, Group of Invasive Haemophilus Infections of the Autonomous Community of Madrid, Spain, Analysis of invasive Haemophilus influenzae infections after extensive vaccination against H. influenzae type b, J Clin Microbiol, 2004;42(2):524-9","journal-title":"J Clin Microbiol"},{"issue":"7","key":"ref53","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1128\/JCM.41.7.3064-3069.2003","article-title":"Invasive disease due to nontypeable Haemophilus influenzae among children in Arkansas","volume":"41","author":"O\u2019Neill JM, St Geme JW, Cutter D, Adderson EE, Anyanwu J, Jacobs RF","year":"2003","unstructured":"53. O\u2019Neill JM, St Geme JW, Cutter D, Adderson EE, Anyanwu J, Jacobs RF, Invasive disease due to nontypeable Haemophilus influenzae among children in Arkansas, J Clin Microbiol, 2003;41(7):3064-9","journal-title":"J Clin Microbiol"},{"issue":"3","key":"ref54","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3201\/eid2303.161552","article-title":"Epidemiology of Invasive Haemophilus influenzae Disease, Europe, 2007-2014","volume":"23","author":"Whittaker R, Economopoulou A, Dias JG, Bancroft E, Ramliden M, Celentano LP, European Centre for Disease Prevention and Control Country Experts for Invasive Haemophilus influenzae Disease","year":"2017","unstructured":"54. Whittaker R, Economopoulou A, Dias JG, Bancroft E, Ramliden M, Celentano LP, European Centre for Disease Prevention and Control Country Experts for Invasive Haemophilus influenzae Disease, Epidemiology of Invasive Haemophilus influenzae Disease, Europe, 2007-2014, Emerg Infect Dis, 2017;23(3):396-404","journal-title":"Emerg Infect Dis"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.jiac.2020.05.006","article-title":"Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in 2010: general view of the pathogens\u2019 antibacterial susceptibility","volume":"21","author":"Yanagihara K, Matsumoto T, Tokimatsu I, Tsukada H, Fujikura Y, Miki M","year":"2015","unstructured":"55. Yanagihara K, Matsumoto T, Tokimatsu I, Tsukada H, Fujikura Y, Miki M, Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in 2010: general view of the pathogens\u2019 antibacterial susceptibility, J Infect Chemother, 2015;21410-420","journal-title":"J Infect Chemother"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12866-015-0350-7","article-title":"Nasopharyngeal carriage and antimicrobial susceptibility of Haemophilus influenzae among children younger than 5 years of age in Beijing, China","volume":"15","author":"Zhu H, Wang A, Tong J, Yuan L, Gao W, Shi W","year":"2015","unstructured":"56. Zhu H, Wang A, Tong J, Yuan L, Gao W, Shi W, Nasopharyngeal carriage and antimicrobial susceptibility of Haemophilus influenzae among children younger than 5 years of age in Beijing, China, BMC Microbiol, 2015;156","journal-title":"BMC Microbiol"},{"issue":"2","key":"ref57","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s10156-009-0011-6","article-title":"Diverse mutations in the ftsI gene in ampicillin-resistant Haemophilus influenzae isolates from pediatric patients with acute otitis media","volume":"16","author":"Kishii K, Chiba N, Morozumi M, Hamano-Hasegawa K, Kurokawa I, Masaki J","year":"2010","unstructured":"57. Kishii K, Chiba N, Morozumi M, Hamano-Hasegawa K, Kurokawa I, Masaki J, Diverse mutations in the ftsI gene in ampicillin-resistant Haemophilus influenzae isolates from pediatric patients with acute otitis media, J Infect Chemother, 2010;16(2):87-93","journal-title":"J Infect Chemother"},{"key":"ref58","article-title":"Principles and Practice of Pediatric Infectious Diseases","author":"Long SS, Prober CG, Fischer M, Kimberlin DW","year":"2023","unstructured":"58. Long SS, Prober CG, Fischer M, Kimberlin DW, Principles and Practice of Pediatric Infectious Diseases, Amsterdam:Elsevier, 2023;"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"G5","DOI":"10.1016\/j.vaccine.2008.11.006","article-title":"Microbiology of otitis media: a moving target","volume":"26","author":"Vergison A","year":"2008","unstructured":"59. Vergison A, Microbiology of otitis media: a moving target, Vaccine, 2008;26(Suppl 7):G5-10","journal-title":"Vaccine"},{"issue":"12","key":"ref60","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/j.ijporl.2010.09.022","article-title":"Otitis media across nine countries: disease burden and management","volume":"74","author":"Arguedas A, Kvaerner K, Liese J, Schilder AG, Pelton SI","year":"2010","unstructured":"60. Arguedas A, Kvaerner K, Liese J, Schilder AG, Pelton SI, Otitis media across nine countries: disease burden and management, Int J Pediatr Otorhinolaryngol, 2010;74(12):1419-24","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"7","key":"ref61","doi-asserted-by":"publisher","first-page":"486e1","DOI":"10.1016\/j.cmi.2017.01.010","article-title":"Prospective evaluation of the aetiology of acute otitis media with spontaneous tympanic membrane perforation","volume":"23","author":"Marchisio P, Esposito S, Picca M, Baggi E, Terranova L, Orenti A, Milan AOM Study Group","year":"2017","unstructured":"61. Marchisio P, Esposito S, Picca M, Baggi E, Terranova L, Orenti A, Milan AOM Study Group, Prospective evaluation of the aetiology of acute otitis media with spontaneous tympanic membrane perforation, Clin Microbiol Infect, 2017;23(7):486e1-486.e6","journal-title":"Clin Microbiol Infect"},{"issue":"22","key":"ref62","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1056\/NEJMra0800353","article-title":"Infection in the pathogenesis and course of chronic obstructive pulmonary disease","volume":"359","author":"Sethi S, Murphy TF","year":"2008","unstructured":"62. Sethi S, Murphy TF, Infection in the pathogenesis and course of chronic obstructive pulmonary disease, N Engl J Med, 2008;359(22):2355-65","journal-title":"N Engl J Med"},{"issue":"4","key":"ref63","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1128\/JCM.40.4.1546-1548.2002","article-title":"Production of BRO beta-lactamases and resistance to complement in European Moraxella catarrhalis isolates","volume":"40","author":"Schmitz FJ, Beeck A, Perdikouli M, Boos M, Mayer S, Scheuring S","year":"2002","unstructured":"63. Schmitz FJ, Beeck A, Perdikouli M, Boos M, Mayer S, Scheuring S, Production of BRO beta-lactamases and resistance to complement in European Moraxella catarrhalis isolates, J Clin Microbiol, 2002;40(4):1546-8","journal-title":"J Clin Microbiol"},{"issue":"3","key":"ref64","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1128\/IAI.74.3.1588-1596.2006","article-title":"Biofilm formation by Moraxella catarrhalis in vitro: roles of the UspA1 adhesin and the Hag hemagglutinin","volume":"74","author":"Pearson MM, Laurence CA, Guinn SE, Hansen EJ","year":"2006","unstructured":"64. Pearson MM, Laurence CA, Guinn SE, Hansen EJ, Biofilm formation by Moraxella catarrhalis in vitro: roles of the UspA1 adhesin and the Hag hemagglutinin, Infect Immun, 2006;74(3):1588-96","journal-title":"Infect Immun"},{"issue":"2","key":"ref65","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1001\/jama.296.2.202","article-title":"Direct detection of bacterial biofilms on the middle-ear mucosa of children with chronic otitis media","volume":"296","author":"Hall-Stoodley L, Hu FZ, Gieseke A, Nistico L, Nguyen D, Hayes J","year":"2006","unstructured":"65. Hall-Stoodley L, Hu FZ, Gieseke A, Nistico L, Nguyen D, Hayes J, Direct detection of bacterial biofilms on the middle-ear mucosa of children with chronic otitis media, JAMA, 2006;296(2):202-11","journal-title":"JAMA"},{"issue":"3","key":"ref66","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1111\/j.1462-5822.2006.00821.x","article-title":"Moraxella catarrhalis is internalized in respiratory epithelial cells by a trigger-like mechanism and initiates a TLR2-and partly NOD1-dependent inflammatory immune response","volume":"9","author":"Slevogt H, Seybold J, Tiwari KN, Hocke AC, Jonatat C, Dietel S","year":"2007","unstructured":"66. Slevogt H, Seybold J, Tiwari KN, Hocke AC, Jonatat C, Dietel S, Moraxella catarrhalis is internalized in respiratory epithelial cells by a trigger-like mechanism and initiates a TLR2-and partly NOD1-dependent inflammatory immune response, Cell Microbiol, 2007;9(3):694-707","journal-title":"Cell Microbiol"},{"issue":"6","key":"ref67","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1093\/infdis\/169.6.1312","article-title":"Epidemiology of Moraxella catarrhalis in children during the first 2 years of life: relationship to otitis media","volume":"169","author":"Faden H, Harabuchi Y, Hong JJ","year":"1994","unstructured":"67. Faden H, Harabuchi Y, Hong JJ, Epidemiology of Moraxella catarrhalis in children during the first 2 years of life: relationship to otitis media, J Infect Dis, 1994;169(6):1312-7","journal-title":"J Infect Dis"},{"issue":"6","key":"ref68","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1086\/516477","article-title":"Relationship between nasopharyngeal colonization and the development of otitis media in children. Tonawanda\/Williamsville Pediatrics","volume":"175","author":"Faden H, Duffy L, Wasielewski R, Wolf J, Krystofik D, Tung Y","year":"1997","unstructured":"68. Faden H, Duffy L, Wasielewski R, Wolf J, Krystofik D, Tung Y, Relationship between nasopharyngeal colonization and the development of otitis media in children. Tonawanda\/Williamsville Pediatrics, J Infect Dis, 1997;175(6):1440-5","journal-title":"J Infect Dis"},{"issue":"5A","key":"ref69","doi-asserted-by":"publisher","first-page":"9S","DOI":"10.1016\/0002-9343(90)90254-b","article-title":"Respiratory infections caused by Branhamella catarrhalis. Selected epidemiologic features","volume":"88","author":"Sarubbi FA, Myers JW, Williams JJ, Shell CG","year":"1990","unstructured":"69. Sarubbi FA, Myers JW, Williams JJ, Shell CG, Respiratory infections caused by Branhamella catarrhalis. Selected epidemiologic features, Am J Med, 1990;88(5A):9S-14S","journal-title":"Am J Med"},{"issue":"2","key":"ref70","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s15010-002-3124-8","article-title":"Two-year periodicity of respiratory syncytial virus epidemics in Switzerland","volume":"31","author":"Duppenthaler A, Gorgievski-Hrisoho M, Frey U, Aebi C","year":"2003","unstructured":"70. Duppenthaler A, Gorgievski-Hrisoho M, Frey U, Aebi C, Two-year periodicity of respiratory syncytial virus epidemics in Switzerland, Infection, 2003;31(2):75-80","journal-title":"Infection"},{"issue":"2","key":"ref71","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1164\/rccm.200412-1747OC","article-title":"Moraxella catarrhalis in chronic obstructive pulmonary disease: burden of disease and immune response","volume":"172","author":"Murphy TF, Brauer AL, Grant BJ, Sethi S","year":"2005","unstructured":"71. Murphy TF, Brauer AL, Grant BJ, Sethi S, Moraxella catarrhalis in chronic obstructive pulmonary disease: burden of disease and immune response, Am J Respir Crit Care Med, 2005;172(2):195-9","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"ref72","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1086\/647933","article-title":"Acute otitis media caused by Moraxella catarrhalis: epidemiologic and clinical characteristics","volume":"49","author":"Broides A, Dagan R, Greenberg D, Givon-Lavi N, Leibovitz E","year":"2009","unstructured":"72. Broides A, Dagan R, Greenberg D, Givon-Lavi N, Leibovitz E, Acute otitis media caused by Moraxella catarrhalis: epidemiologic and clinical characteristics, Clin Infect Dis, 2009;49(11):1641-7","journal-title":"Clin Infect Dis"},{"issue":"3","key":"ref73","doi-asserted-by":"publisher","first-page":"e20170181","DOI":"10.1542\/peds.2017-0181","article-title":"Epidemiology of Acute Otitis Media in the Postpneumococcal Conjugate Vaccine Era","volume":"140","author":"Kaur R, Morris M, Pichichero ME","year":"2017","unstructured":"73. Kaur R, Morris M, Pichichero ME, Epidemiology of Acute Otitis Media in the Postpneumococcal Conjugate Vaccine Era, Pediatrics, 2017;140(3):e20170181","journal-title":"Pediatrics"},{"key":"ref74","first-page":"770","article-title":"Acinetobacter Achromobacter Chrys-eobacterium Moraxella and other nonfermentative Gram-negative rods","author":"Schreckenberger PC, Daneshvar MI, Hollis DG, Murray PR, Baron EJ, Jorgensen JH","year":"2003","unstructured":"74. Schreckenberger PC, Daneshvar MI, Hollis DG, Murray PR, Baron EJ, Jorgensen JH, Acinetobacter Achromobacter Chrys-eobacterium Moraxella and other nonfermentative Gram-negative rods, Manual of Clinical Microbiology, Washington, DC:ASM Press, 2003;770-802","journal-title":"Manual of Clinical Microbiology"},{"issue":"3","key":"ref75","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.jmii.2016.08.003","article-title":"Antimicrobial susceptibility to \u03b2-lactam antibiotics and production of BRO \u03b2-lactamase in clinical isolates of Moraxella catarrhalis from a Japanese hospital","volume":"50","author":"Yamada K, Arai K, Saito R","year":"2017","unstructured":"75. Yamada K, Arai K, Saito R, Antimicrobial susceptibility to \u03b2-lactam antibiotics and production of BRO \u03b2-lactamase in clinical isolates of Moraxella catarrhalis from a Japanese hospital, J Microbiol Immunol Infect, 2017;50(3):386-389","journal-title":"J Microbiol Immunol Infect"},{"issue":"6","key":"ref76","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10156-009-0719-3","article-title":"Antimicrobial susceptibility of pathogens isolated from more than 10,000 patients with infectious respiratory diseases: a 25-year longitudinal study","volume":"15","author":"Goto H, Shimada K, Ikemoto H, Oguri T, Study Group on Antimicrobial Susceptibility of Pathogens Isolated from Respiratory Infections","year":"2009","unstructured":"76. Goto H, Shimada K, Ikemoto H, Oguri T, Study Group on Antimicrobial Susceptibility of Pathogens Isolated from Respiratory Infections, Antimicrobial susceptibility of pathogens isolated from more than 10,000 patients with infectious respiratory diseases: a 25-year longitudinal study, J Infect Chemother, 2009;15(6):347-60","journal-title":"J Infect Chemother"},{"issue":"1","key":"ref77","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jiac.2013.06.003","article-title":"The frequency of BRO \u03b2-lactamase and its relationship to antimicrobial susceptibility and serum resistance in Moraxella catarrhalis","volume":"20","author":"Saito R, Nonaka S, Fujinami Y, Matsuoka S, Nakajima S, Nishiyama H","year":"2014","unstructured":"77. Saito R, Nonaka S, Fujinami Y, Matsuoka S, Nakajima S, Nishiyama H, The frequency of BRO \u03b2-lactamase and its relationship to antimicrobial susceptibility and serum resistance in Moraxella catarrhalis, J Infect Chemother, 2014;20(1):6-8","journal-title":"J Infect Chemother"},{"issue":"3","key":"ref78","first-page":"103","article-title":"Tetracycline resistance in Moraxella catarrhalis clinical strains isolated in Poland","volume":"43","author":"Kr\u00f3l-Turmi\u0144ska K, Olender A, Bogut A","year":"2020","unstructured":"78. Kr\u00f3l-Turmi\u0144ska K, Olender A, Bogut A, Tetracycline resistance in Moraxella catarrhalis clinical strains isolated in Poland, New Mi-crobiol, 2020;43(3):103-106","journal-title":"New Mi-crobiol"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"ii3","DOI":"10.1093\/jac\/dki297","article-title":"The Alexander Project: the benefits from a decade of surveillance","volume":"56","author":"Felmingham D, White AR, Jacobs MR, Appelbaum PC, Poupard J, Miller LA","year":"2005","unstructured":"79. Felmingham D, White AR, Jacobs MR, Appelbaum PC, Poupard J, Miller LA, The Alexander Project: the benefits from a decade of surveillance, J Antimicrob Chemother, 2005;56(Suppl 2):ii3-ii21","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"ref80","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1128\/MMBR.00007-09","article-title":"Molecular aspects of Moraxella catarrhalis pathogenesis","volume":"73","author":"de Vries SP, Bootsma HJ, Hays JP, Hermans PW","year":"2009","unstructured":"80. de Vries SP, Bootsma HJ, Hays JP, Hermans PW, Molecular aspects of Moraxella catarrhalis pathogenesis, Microbiol Mol Biol Rev, 2009;73(3):389-406","journal-title":"Microbiol Mol Biol Rev"},{"issue":"23","key":"ref81","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1016\/j.vaccine.2019.04.041","article-title":"Safety and immunogenicity of non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine","volume":"37","author":"Van Damme P, Leroux-Roels G, Vandermeulen C, De Ryck I, Tasciotti A, Dozot M","year":"2019","unstructured":"81. Van Damme P, Leroux-Roels G, Vandermeulen C, De Ryck I, Tasciotti A, Dozot M, Safety and immunogenicity of non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine, Vaccine, 2019;37(23):3113-3122","journal-title":"Vaccine"},{"issue":"7","key":"ref82","doi-asserted-by":"publisher","first-page":"975","DOI":"10.3390\/foods11070975","article-title":"Isolates from Foods of Animal Origin-The Genetic Basis of Acquired Resistance","volume":"11","author":"Zarzecka U, Zakrzewski AJ, Chaj\u0119cka-Wierzchowska W, Zadernowska A, Linezolid-Resistant Enterococcus spp","year":"2022","unstructured":"82. Zarzecka U, Zakrzewski AJ, Chaj\u0119cka-Wierzchowska W, Zadernowska A, Linezolid-Resistant Enterococcus spp, Isolates from Foods of Animal Origin-The Genetic Basis of Acquired Resistance, Foods, 2022;11(7):975","journal-title":"Foods"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ijfoodmicro.2019.01.002","article-title":"Detection of oxazolidinone and phenicol resistant enterococcal isolates from duck feces and carcasses","volume":"293","author":"Na SH, Moon DC, Choi MJ, Oh SJ, Jung DY, Kang HY","year":"2019","unstructured":"83. Na SH, Moon DC, Choi MJ, Oh SJ, Jung DY, Kang HY, Detection of oxazolidinone and phenicol resistant enterococcal isolates from duck feces and carcasses, Int J Food Microbiol, 2019;29353-59","journal-title":"Int J Food Microbiol"},{"issue":"7","key":"ref84","doi-asserted-by":"publisher","first-page":"mgen001055","DOI":"10.1099\/mgen.0.001055","article-title":"Emergence of linezolid-resistant Enterococcus faecium in a tertiary hospital in Copenhagen","volume":"9","author":"Misiakou MA, Hertz FB, Sch\u00f8nning K, H\u00e4ussler S, Nielsen KL","year":"2023","unstructured":"84. Misiakou MA, Hertz FB, Sch\u00f8nning K, H\u00e4ussler S, Nielsen KL, Emergence of linezolid-resistant Enterococcus faecium in a tertiary hospital in Copenhagen, Microb Genom, 2023;9(7):mgen001055","journal-title":"Microb Genom"},{"issue":"12","key":"ref85","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1128\/AAC.42.12.3251","article-title":"The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria","volume":"42","author":"Swaney SM, Aoki H, Ganoza MC, Shinabarger DL","year":"1998","unstructured":"85. Swaney SM, Aoki H, Ganoza MC, Shinabarger DL, The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria, Antimicrob Agents Chemother, 1998;42(12):3251-5","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"ref86","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1358\/dot.2000.36.9.593780","article-title":"Linezolid: a new antibiotic","volume":"36","author":"Xiong YQ, Yeaman MR, Bayer AS","year":"2000","unstructured":"86. Xiong YQ, Yeaman MR, Bayer AS, Linezolid: a new antibiotic, Drugs Today (Barc), 2000;36(9):631-9","journal-title":"Drugs Today (Barc)"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.2147\/DDDT.S164515","article-title":"Linezolid: a review of its properties, function, and use in critical care","volume":"12","author":"Hashemian SMR, Farhadi T, Ganjparvar M","year":"2018","unstructured":"87. Hashemian SMR, Farhadi T, Ganjparvar M, Linezolid: a review of its properties, function, and use in critical care, Drug Des Devel Ther, 2018;121759-1767","journal-title":"Drug Des Devel Ther"},{"issue":"4","key":"ref88","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1128\/AAC.46.4.1080-1085.2002","article-title":"Oxazolidinone antibiotics target the P site on Escherichia coli ribosomes","volume":"46","author":"Aoki H, Ke L, Poppe SM, Poel TJ, Weaver EA, Gadwood RC","year":"2002","unstructured":"88. Aoki H, Ke L, Poppe SM, Poel TJ, Weaver EA, Gadwood RC, Oxazolidinone antibiotics target the P site on Escherichia coli ribosomes, Antimicrob Agents Chemother, 2002;46(4):1080-5","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"ref89","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1128\/AAC.05702-11","article-title":"Resistance to linezolid caused by modifications at its binding site on the ribosome","volume":"56","author":"Long KS, Vester B","year":"2012","unstructured":"89. Long KS, Vester B, Resistance to linezolid caused by modifications at its binding site on the ribosome, Antimicrob Agents Chemother, 2012;56(2):603-12","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"ref90","doi-asserted-by":"publisher","first-page":"e0167042","DOI":"10.1371\/journal.pone.0167042","article-title":"Detection of a cfr(B) Variant in German Enterococcus faecium Clinical Isolates and the Impact on Linezolid Resistance in Enterococcus spp","volume":"11","author":"Bender JK, Fleige C, Klare I, Fiedler S, Mischnik A, Mutters NT","year":"2016","unstructured":"90. Bender JK, Fleige C, Klare I, Fiedler S, Mischnik A, Mutters NT, Detection of a cfr(B) Variant in German Enterococcus faecium Clinical Isolates and the Impact on Linezolid Resistance in Enterococcus spp, PLoS One, 2016;11(11):e0167042","journal-title":"PLoS One"},{"issue":"3","key":"ref91","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1093\/jac\/dkv391","article-title":"Horizontal gene transmission of the cfr gene to MRSA and Enterococcus: role of Staphylococcus epidermidis as a reservoir and alternative pathway for the spread of linezolid resistance","volume":"71","author":"Cafini F, Nguyen le TT, Higashide M, Rom\u00e1n F, Prieto J, Morikawa K","year":"2016","unstructured":"91. Cafini F, Nguyen le TT, Higashide M, Rom\u00e1n F, Prieto J, Morikawa K, Horizontal gene transmission of the cfr gene to MRSA and Enterococcus: role of Staphylococcus epidermidis as a reservoir and alternative pathway for the spread of linezolid resistance, J Antimicrob Chemother, 2016;71(3):587-92","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"ref92","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1128\/AAC.06091-11","article-title":"First report of the multidrug resistance gene cfr in Enterococcus faecalis of animal origin","volume":"56","author":"Liu Y, Wang Y, Wu C, Shen Z, Schwarz S, Du XD","year":"2012","unstructured":"92. Liu Y, Wang Y, Wu C, Shen Z, Schwarz S, Du XD, First report of the multidrug resistance gene cfr in Enterococcus faecalis of animal origin, Antimicrob Agents Chemother, 2012;56(3):1650-4","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"ref93","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.1128\/AAC.00419-12","article-title":"Transferable plasmid-mediated resistance to linezolid due to cfr in a human clinical isolate of Enterococcus faecalis","volume":"56","author":"Diaz L, Kiratisin P, Mendes RE, Panesso D, Singh KV, Arias CA","year":"2012","unstructured":"93. Diaz L, Kiratisin P, Mendes RE, Panesso D, Singh KV, Arias CA, Transferable plasmid-mediated resistance to linezolid due to cfr in a human clinical isolate of Enterococcus faecalis, Antimicrob Agents Chemother, 2012;56(7):3917-22","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"ref94","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1128\/AAC.00183-11","article-title":"Inactivation of the indigenous methyltransferase RlmN in Staphylococcus aureus increases linezolid resistance","volume":"55","author":"LaMarre JM, Howden BP, Mankin AS","year":"2011","unstructured":"94. LaMarre JM, Howden BP, Mankin AS, Inactivation of the indigenous methyltransferase RlmN in Staphylococcus aureus increases linezolid resistance, Antimicrob Agents Chemother, 2011;55(6):2989-91","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"ref95","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1021\/acsinfecdis.7b00251","article-title":"Antibiotic Resistance ABC-F Proteins: Bringing Target Protection into the Limelight","volume":"4","author":"Sharkey LKR, O'Neill AJ","year":"2018","unstructured":"95. Sharkey LKR, O'Neill AJ, Antibiotic Resistance ABC-F Proteins: Bringing Target Protection into the Limelight, ACS Infect Dis, 2018;4(3):239-246","journal-title":"ACS Infect Dis"},{"issue":"1","key":"ref96","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00228-014-1775-x","article-title":"Linezolid versus vancomycin for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a systematic review employing meta-analysis","volume":"71","author":"Wang Y, Zou Y, Xie J, Wang T, Zheng X, He H","year":"2015","unstructured":"96. Wang Y, Zou Y, Xie J, Wang T, Zheng X, He H, Linezolid versus vancomycin for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a systematic review employing meta-analysis, Eur J Clin Pharmacol, 2015;71(1):107-15","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"ref97","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1093\/jac\/dkv438","article-title":"Detection in Italy of two clinical Enterococcus faecium isolates carrying both the oxazolidinone and phenicol resistance gene optrA and a silent multiresistance gene cfr","volume":"71","author":"Brenciani A, Morroni G, Vincenzi C, Manso E, Mingoia M, Giovanetti E","year":"2016","unstructured":"97. Brenciani A, Morroni G, Vincenzi C, Manso E, Mingoia M, Giovanetti E, Detection in Italy of two clinical Enterococcus faecium isolates carrying both the oxazolidinone and phenicol resistance gene optrA and a silent multiresistance gene cfr, J Antimicrob Chemother, 2016;71(4):1118-9","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"ref98","doi-asserted-by":"publisher","first-page":"1095e1","DOI":"10.1016\/j.cmi.2015.08.007","article-title":"Enterococcal isolates carrying the novel oxazolidinone resistance gene optrA from hospitals in Zhejiang, Guangdong, and Henan, China, 2010-2014","volume":"21","author":"Cai J, Wang Y, Schwarz S, Lv H, Li Y, Liao K","year":"2015","unstructured":"98. Cai J, Wang Y, Schwarz S, Lv H, Li Y, Liao K, Enterococcal isolates carrying the novel oxazolidinone resistance gene optrA from hospitals in Zhejiang, Guangdong, and Henan, China, 2010-2014, Clin Microbiol Infect, 2015;21(12):1095e1-4","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"ref99","doi-asserted-by":"publisher","first-page":"7490","DOI":"10.1128\/AAC.01256-16","article-title":"Nationwide Surveillance of Novel Oxazolidinone Resistance Gene optrA in Enterococcus Isolates in China from 2004 to 2014","volume":"60","author":"Cui L, Wang Y, Lv Y, Wang S, Song Y, Li Y","year":"2016","unstructured":"99. Cui L, Wang Y, Lv Y, Wang S, Song Y, Li Y, Nationwide Surveillance of Novel Oxazolidinone Resistance Gene optrA in Enterococcus Isolates in China from 2004 to 2014, Antimicrob Agents Chemother, 2016;60(12):7490-7493","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"ref100","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1093\/jac\/dkw016","article-title":"Genetic environment of the transferable oxazolidinone\/phenicol resistance gene optrA in Enterococcus faecalis isolates of human and animal origin","volume":"71","author":"He T, Shen Y, Schwarz S, Cai J, Lv Y, Li J","year":"2016","unstructured":"100. He T, Shen Y, Schwarz S, Cai J, Lv Y, Li J, Genetic environment of the transferable oxazolidinone\/phenicol resistance gene optrA in Enterococcus faecalis isolates of human and animal origin, J Antimicrob Chemother, 2016;71(6):1466-73","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"ref101","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1093\/jac\/dkw488","article-title":"Retrospective analysis of genome sequences revealed the wide dissemination of optrA in Gram-positive bacteria","volume":"72","author":"Huang J, Chen L, Wu Z, Wang L","year":"2017","unstructured":"101. Huang J, Chen L, Wu Z, Wang L, Retrospective analysis of genome sequences revealed the wide dissemination of optrA in Gram-positive bacteria, J Antimicrob Chemother, 2017;72(2):614-616","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"ref102","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1093\/jac\/dkw040","article-title":"Co-location of the oxazolidinone resistance genes optrA and cfr on a multiresistance plasmid from Staphylococcus sciuri","volume":"71","author":"Li D, Wang Y, Schwarz S, Cai J, Fan R, Li J","year":"2016","unstructured":"102. Li D, Wang Y, Schwarz S, Cai J, Fan R, Li J, Co-location of the oxazolidinone resistance genes optrA and cfr on a multiresistance plasmid from Staphylococcus sciuri, J Antimicrob Chemother, 2016;71(6):1474-8","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"ref103","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1093\/jac\/dkv116","article-title":"A novel gene, optrA, that confers transferable resistance to oxazolidinones and phenicols and its presence in Enterococcus faecalis and Enterococcus faecium of human and animal origin","volume":"70","author":"Wang Y, Lv Y, Cai J, Schwarz S, Cui L, Hu Z","year":"2015","unstructured":"103. Wang Y, Lv Y, Cai J, Schwarz S, Cui L, Hu Z, A novel gene, optrA, that confers transferable resistance to oxazolidinones and phenicols and its presence in Enterococcus faecalis and Enterococcus faecium of human and animal origin, J Antimicrob Chemother, 2015;70(8):2182-90","journal-title":"J Antimicrob Chemother"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jgar.2017.04.001","article-title":"First detection of linezolid resistance due to the optrA gene in enterococci isolated from food products in Denmark","volume":"9","author":"Cavaco LM, Korsgaard H, Kaas RS, Seyfarth AM, Leekitcharoenphon P, Hendriksen RS","year":"2017","unstructured":"104. Cavaco LM, Korsgaard H, Kaas RS, Seyfarth AM, Leekitcharoenphon P, Hendriksen RS, First detection of linezolid resistance due to the optrA gene in enterococci isolated from food products in Denmark, J Glob Antimicrob Resist, 2017;9128-129","journal-title":"J Glob Antimicrob Resist"},{"issue":"7","key":"ref105","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1093\/jac\/dky088","article-title":"Characterization of poxtA, a novel phenicol-oxazolidinone-tetracycline resistance gene from an MRSA of clinical origin","volume":"73","author":"Antonelli A, D\u2019Andrea MM, Brenciani A, Galeotti CL, Morroni G, Pollini S","year":"2018","unstructured":"105. Antonelli A, D\u2019Andrea MM, Brenciani A, Galeotti CL, Morroni G, Pollini S, Characterization of poxtA, a novel phenicol-oxazolidinone-tetracycline resistance gene from an MRSA of clinical origin, J Antimicrob Chemother, 2018;73(7):1763-1769","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"ref106","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1093\/jac\/dkab116","article-title":"Genetic features of the poxtA linezolid resistance gene in human enterococci from France","volume":"76","author":"Dejoies L, Sassi M, Schutz S, Moreaux J, Zouari A, Potrel S","year":"2021","unstructured":"106. Dejoies L, Sassi M, Schutz S, Moreaux J, Zouari A, Potrel S, Genetic features of the poxtA linezolid resistance gene in human enterococci from France, J Antimicrob Chemother, 2021;76(8):1978-1985","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"ref107","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1128\/AAC.50.4.1156-1163.2006","article-title":"Distribution of florfenicol resistance genes fexA and cfr among chloramphenicol-resistant Staphylococcus isolates","volume":"50","author":"Kehrenberg C, Schwarz S","year":"2006","unstructured":"107. Kehrenberg C, Schwarz S, Distribution of florfenicol resistance genes fexA and cfr among chloramphenicol-resistant Staphylococcus isolates, Antimicrob Agents Chemother, 2006;50(4):1156-63","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"ref108","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s10096-017-2934-7","article-title":"Linezolid-resistant enterococci in Polish hospitals: species, clonality and determinants of linezolid resistance","volume":"36","author":"Gawryszewska I, \u017babicka D, Hryniewicz W, Sadowy E","year":"2017","unstructured":"108. Gawryszewska I, \u017babicka D, Hryniewicz W, Sadowy E, Linezolid-resistant enterococci in Polish hospitals: species, clonality and determinants of linezolid resistance, Eur J Clin Microbiol Infect Dis, 2017;36(7):1279-1286","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"2","key":"ref109","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/jac\/dkw450","article-title":"Linezolid: a promising option in the treatment of Gram-positives","volume":"72","author":"Zahedi Bialvaei A, Rahbar M, Yousefi M, Asgharzadeh M, Samadi Kafil H","year":"2017","unstructured":"109. Zahedi Bialvaei A, Rahbar M, Yousefi M, Asgharzadeh M, Samadi Kafil H, Linezolid: a promising option in the treatment of Gram-positives, J Antimicrob Chemother, 2017;72(2):354-364","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"ref110","doi-asserted-by":"publisher","first-page":"4068","DOI":"10.3168\/jds.2019-17395","article-title":"Ready-to-eat dairy products as a source of multidrug-resistant Enterococcus strains: Phenotypic and genotypic characteristics","volume":"103","author":"Chaj\u0119cka-Wierzchowska W, Zadernowska A, Garc\u00eda-Solache M","year":"2020","unstructured":"110. Chaj\u0119cka-Wierzchowska W, Zadernowska A, Garc\u00eda-Solache M, Ready-to-eat dairy products as a source of multidrug-resistant Enterococcus strains: Phenotypic and genotypic characteristics, J Dairy Sci, 2020;103(5):4068-4077","journal-title":"J Dairy Sci"},{"issue":"3","key":"ref111","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1002\/jsfa.9285","article-title":"Enterococci from ready-to-eat food-horizontal gene transfer of antibiotic resistance genes and genotypic characterization by PCR melting profile","volume":"99","author":"Chaj\u0119cka-Wierzchowska W, Zadernowska A, Zarzecka U, Zakrzewski A, Gajewska J","year":"2019","unstructured":"111. Chaj\u0119cka-Wierzchowska W, Zadernowska A, Zarzecka U, Zakrzewski A, Gajewska J, Enterococci from ready-to-eat food-horizontal gene transfer of antibiotic resistance genes and genotypic characterization by PCR melting profile, J Sci Food Agric, 2019;99(3):1172-1179","journal-title":"J Sci Food Agric"},{"issue":"11","key":"ref112","doi-asserted-by":"publisher","first-page":"M2799","DOI":"10.1111\/1750-3841.13523","article-title":"Diversity of Antibiotic Resistance Genes in Enterococcus Strains Isolated from Ready-to-Eat Meat Products","volume":"81","author":"Chaj\u0119cka-Wierzchowska W, Zadernowska A, \u0141aniewska-Trokenheim \u0141","year":"2016","unstructured":"112. Chaj\u0119cka-Wierzchowska W, Zadernowska A, \u0141aniewska-Trokenheim \u0141, Diversity of Antibiotic Resistance Genes in Enterococcus Strains Isolated from Ready-to-Eat Meat Products, J Food Sci, 2016;81(11):M2799-M2807","journal-title":"J Food Sci"},{"issue":"12","key":"ref113","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.3390\/microorganisms8122021","article-title":"Detection of Oxazolidinone Resistance Genes and Characterization of Genetic Environments in Enterococci of Swine Origin, Italy","volume":"8","author":"Fioriti S, Morroni G, Coccitto SN, Brenciani A, Antonelli A, Di Pilato V","year":"2020","unstructured":"113. Fioriti S, Morroni G, Coccitto SN, Brenciani A, Antonelli A, Di Pilato V, Detection of Oxazolidinone Resistance Genes and Characterization of Genetic Environments in Enterococci of Swine Origin, Italy, Microorganisms, 2020;8(12):2021","journal-title":"Microorganisms"},{"issue":"8","key":"ref114","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/jac\/dkz198","article-title":"Detection of the phenicol-oxazolidinone-tetracycline resistance gene poxtA in Enterococcus faecium and Enterococcus faecalis of food-producing animal origin in China","volume":"74","author":"Lei CW, Kang ZZ, Wu SK, Chen YP, Kong LH, Wang HN","year":"2019","unstructured":"114. Lei CW, Kang ZZ, Wu SK, Chen YP, Kong LH, Wang HN, Detection of the phenicol-oxazolidinone-tetracycline resistance gene poxtA in Enterococcus faecium and Enterococcus faecalis of food-producing animal origin in China, J Antimicrob Chemother, 2019;74(8):2459-2461","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"ref115","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.diagmicrobio.2018.01.027","article-title":"Prolonged linezolid use is associated with the development of linezolid-resistant Enterococcus faecium","volume":"91","author":"Smith TT, Tamma PD, Do TB, Dzintars KE, Zhao Y, Cosgrove SE","year":"2018","unstructured":"115. Smith TT, Tamma PD, Do TB, Dzintars KE, Zhao Y, Cosgrove SE, Prolonged linezolid use is associated with the development of linezolid-resistant Enterococcus faecium, Diagn Microbiol Infect Dis, 2018;91(2):161-163","journal-title":"Diagn Microbiol Infect Dis"},{"key":"ref116","article-title":"Antibiotic Resistance & Patient Safety Portal","author":"Centers for Disease Control and Prevention (CDC)","unstructured":"116. Centers for Disease Control and Prevention (CDC), Antibiotic Resistance & Patient Safety Portal, Available from: https:\/\/arpsp.cdc.gov\/profile\/antibiotic-resistance\/mdr-pseudomonas-aeruginosa"},{"issue":"4","key":"ref117","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1080\/14787210.2018.1447381","article-title":"Ceftolozane\/tazobactam: place in therapy","volume":"16","author":"Giacobbe DR, Bassetti M, De Rosa FG, Del Bono V, Grossi PA, Menichetti F, ISGRI-SITA (Italian Study Group on Resistant Infections of the Societ\u00e0 Italiana Terapia Antinfettiva)","year":"2018","unstructured":"117. Giacobbe DR, Bassetti M, De Rosa FG, Del Bono V, Grossi PA, Menichetti F, ISGRI-SITA (Italian Study Group on Resistant Infections of the Societ\u00e0 Italiana Terapia Antinfettiva), Ceftolozane\/tazobactam: place in therapy, Expert Rev Anti Infect Ther, 2018;16(4):307-320","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"6","key":"ref118","doi-asserted-by":"publisher","first-page":"106196","DOI":"10.1016\/j.ijantimicag.2020.106196","article-title":"Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired \u03b2-lactamases: 2020 update","volume":"56","author":"Del Barrio-Tofi\u00f1o E, L\u00f3pez-Causap\u00e9 C, Oliver A","year":"2020","unstructured":"118. Del Barrio-Tofi\u00f1o E, L\u00f3pez-Causap\u00e9 C, Oliver A, Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired \u03b2-lactamases: 2020 update, Int J Antimicrob Agents, 2020;56(6):106196","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"ref119","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/jac\/dkx136","article-title":"Activity of ceftolozane\/tazobactam against surveillance and 'problem' Enterobacteriaceae. Pseudomonas aeruginosa and non-fermenters from the British Isles","volume":"72","author":"Livermore DM, Mushtaq S, Meunier D, Hopkins KL, Hill R, Adkin R, BSAC Resistance Surveillance Standing Committee","year":"2017","unstructured":"119. Livermore DM, Mushtaq S, Meunier D, Hopkins KL, Hill R, Adkin R, BSAC Resistance Surveillance Standing Committee, Activity of ceftolozane\/tazobactam against surveillance and 'problem' Enterobacteriaceae. Pseudomonas aeruginosa and non-fermenters from the British Isles, J Antimicrob Chemother, 2017;72(8):2278-2289","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"ref120","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.diagmicrobio.2016.02.014","article-title":"In vitro activity of ceftolozane\/tazobactam against clinical isolates of Pseudomonas aeruginosa in the planktonic and biofilm states","volume":"85","author":"Velez Perez AL, Schmidt-Malan SM, Kohner PC, Karau MJ, Greenwood-Quaintance KE, Patel R","year":"2016","unstructured":"120. Velez Perez AL, Schmidt-Malan SM, Kohner PC, Karau MJ, Greenwood-Quaintance KE, Patel R, In vitro activity of ceftolozane\/tazobactam against clinical isolates of Pseudomonas aeruginosa in the planktonic and biofilm states, Diagn Microbiol Infect Dis, 2016;85(3):356-359","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"2","key":"ref121","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/cid\/ciz816","article-title":"Ceftolozane\/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa","volume":"71","author":"Pogue JM, Kaye KS, Veve MP, Patel TS, Gerlach AT, Davis SL","year":"2020","unstructured":"121. Pogue JM, Kaye KS, Veve MP, Patel TS, Gerlach AT, Davis SL, Ceftolozane\/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa, Clin Infect Dis, 2020;71(2):304-310","journal-title":"Clin Infect Dis"},{"issue":"3","key":"ref122","doi-asserted-by":"publisher","first-page":"106270","DOI":"10.1016\/j.ijantimicag.2020.106270","article-title":"Multicenter study of ceftolozane\/tazobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients","volume":"57","author":"Balandin B, Ballesteros D, Ruiz de Luna R, L\u00f3pez-Vergara L, Pintado V, Sancho-Gonz\u00e1lez M","year":"2021","unstructured":"122. Balandin B, Ballesteros D, Ruiz de Luna R, L\u00f3pez-Vergara L, Pintado V, Sancho-Gonz\u00e1lez M, Multicenter study of ceftolozane\/tazobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients, Int J Antimicrob Agents, 2021;57(3):106270","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"ref123","doi-asserted-by":"publisher","first-page":"e02340","DOI":"10.1128\/AAC.02340-18","article-title":"A Case-Control Study of Real-Life Experience with Ceftolozane-Tazobactam in Patients with Hematologic Malignancy and Pseudomonas aeruginosa Infection","volume":"63","author":"Fern\u00e1ndez-Cruz A, Alba N, Semiglia-Chong MA, Padilla B, Rodr\u00edguez-Mac\u00edas G, Kwon M","year":"2019","unstructured":"123. Fern\u00e1ndez-Cruz A, Alba N, Semiglia-Chong MA, Padilla B, Rodr\u00edguez-Mac\u00edas G, Kwon M, A Case-Control Study of Real-Life Experience with Ceftolozane-Tazobactam in Patients with Hematologic Malignancy and Pseudomonas aeruginosa Infection, Antimicrob Agents Chemother, 2019;63(2):e02340-18","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"ref124","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.3390\/antibiotics10091126","article-title":"Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by Pseudomonas aeruginosa","volume":"10","author":"Daikos GL, da Cunha CA, Rossolini GM, Stone GG, Baillon-Plot N, Tawadrous M","year":"2021","unstructured":"124. Daikos GL, da Cunha CA, Rossolini GM, Stone GG, Baillon-Plot N, Tawadrous M, Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by Pseudomonas aeruginosa, Antibiotics (Basel), 2021;10(9):1126","journal-title":"Antibiotics (Basel)"},{"issue":"1","key":"ref125","doi-asserted-by":"publisher","first-page":"e00115","DOI":"10.1128\/CMR.00115-20","article-title":"New \u03b2-Lactam-\u03b2-Lactamase Inhibitor Combinations","volume":"34","author":"Yahav D, Giske CG, Gr\u0101matniece A, Abodakpi H, Tam VH, Leibovici L","year":"2020","unstructured":"125. Yahav D, Giske CG, Gr\u0101matniece A, Abodakpi H, Tam VH, Leibovici L, New \u03b2-Lactam-\u03b2-Lactamase Inhibitor Combinations, Clin Microbiol Rev, 2020;34(1):e00115-20","journal-title":"Clin Microbiol Rev"},{"issue":"12","key":"ref126","doi-asserted-by":"publisher","first-page":"ofz522","DOI":"10.1093\/ofid\/ofz522","article-title":"Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections","volume":"6","author":"Jorgensen SCJ, Trinh TD, Zasowski EJ, Lagnf AM, Bhatia S, Melvin SM","year":"2019","unstructured":"126. Jorgensen SCJ, Trinh TD, Zasowski EJ, Lagnf AM, Bhatia S, Melvin SM, Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections, Open Forum Infect Dis, 2019;6(12):ofz522","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"ref127","doi-asserted-by":"publisher","first-page":"106517","DOI":"10.1016\/j.ijantimicag.2021.106517","article-title":"Effectiveness of ceftazidime-avibactam for the treatment of infections due to Pseudomonas aeruginosa","volume":"59","author":"Corbella L, Bo\u00e1n J, San-Juan R, Fern\u00e1ndez-Ruiz M, Carretero O, Lora D","year":"2022","unstructured":"127. Corbella L, Bo\u00e1n J, San-Juan R, Fern\u00e1ndez-Ruiz M, Carretero O, Lora D, Effectiveness of ceftazidime-avibactam for the treatment of infections due to Pseudomonas aeruginosa, Int J Antimicrob Agents, 2022;59(2):106517","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"ref128","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3390\/antibiotics9020071","article-title":"Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant Enterobacterales","volume":"9","author":"Vena A, Giacobbe DR, Castaldo N, Cattelan A, Mussini C, Luzzati R","year":"2020","unstructured":"128. Vena A, Giacobbe DR, Castaldo N, Cattelan A, Mussini C, Luzzati R, Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant Enterobacterales, Antibiotics (Basel), 2020;9(2):71","journal-title":"Antibiotics (Basel)"},{"key":"ref129","article-title":"FDA Approves New Treatment for Complicated Urinary Tract and Complicated Intra-abdominal Infections","author":"U.S Food and Drug Administration","unstructured":"129. U.S Food and Drug Administration, FDA Approves New Treatment for Complicated Urinary Tract and Complicated Intra-abdominal Infections, Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-newtreatment-complicated-urinary-tract-and-complicated-intra-abdominal-infections"},{"key":"ref130","article-title":"Recarbrio: EPAR-Product Information","author":"European Medicines Agency","unstructured":"130. European Medicines Agency, Recarbrio: EPAR-Product Information, Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/recarbrio-epar-product-information_en.pdf"},{"issue":"6","key":"ref131","doi-asserted-by":"publisher","first-page":"e02209","DOI":"10.1128\/AAC.02209-16","article-title":"In Vitro Activity of Imipenem-Relebactam against Gram-Negative ESKAPE Pathogens Isolated by Clinical Laboratories in the United States in 2015 (Results from the SMART Global Surveillance Program)","volume":"61","author":"Lob SH, Hackel MA, Kazmierczak KM, Young K, Motyl MR, Karlowsky JA","year":"2017","unstructured":"131. Lob SH, Hackel MA, Kazmierczak KM, Young K, Motyl MR, Karlowsky JA, In Vitro Activity of Imipenem-Relebactam against Gram-Negative ESKAPE Pathogens Isolated by Clinical Laboratories in the United States in 2015 (Results from the SMART Global Surveillance Program), Antimicrob Agents Chemother, 2017;61(6):e02209-16","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"ref132","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1093\/cid\/ciaa381","article-title":"In Vitro Activity of Imipenem\/Relebactam and Ceftolozane\/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United States 2015-2017","volume":"72","author":"Karlowsky JA, Lob SH, Raddatz J, DePestel DD, Young K, Motyl MR","year":"2021","unstructured":"132. Karlowsky JA, Lob SH, Raddatz J, DePestel DD, Young K, Motyl MR, In Vitro Activity of Imipenem\/Relebactam and Ceftolozane\/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United States 2015-2017, Clin Infect Dis, 2021;72(12):2112-2120","journal-title":"Clin Infect Dis"},{"key":"ref133","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jgar.2019.10.028","article-title":"In vitro activity of imipenem\/relebactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples: SMART Surveillance United States 2015-2017","volume":"21","author":"Karlowsky JA, Lob SH, Kazmierczak KM, Young K, Motyl MR, Sahm DF","year":"2020","unstructured":"133. Karlowsky JA, Lob SH, Kazmierczak KM, Young K, Motyl MR, Sahm DF, In vitro activity of imipenem\/relebactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples: SMART Surveillance United States 2015-2017, J Glob Antimicrob Resist, 2020;21223-228","journal-title":"J Glob Antimicrob Resist"},{"issue":"1","key":"ref134","doi-asserted-by":"publisher","first-page":"115418","DOI":"10.1016\/j.diagmicrobio.2021.115418","article-title":"In vitro activity of imipenem-relebactam against various resistance phenotypes\/genotypes of Enterobacterales and Pseudomonas aeruginosa isolated from patients across Canada as part of the CANWARD study 2016-2019","volume":"101","author":"Walkty A, Karlowsky JA, Baxter MR, Adam HJ, Golden A, Lagace-Wiens P, Canadian Antimicrobial Resistance Alliance (CARA)","year":"2021","unstructured":"134. Walkty A, Karlowsky JA, Baxter MR, Adam HJ, Golden A, Lagace-Wiens P, Canadian Antimicrobial Resistance Alliance (CARA), In vitro activity of imipenem-relebactam against various resistance phenotypes\/genotypes of Enterobacterales and Pseudomonas aeruginosa isolated from patients across Canada as part of the CANWARD study 2016-2019, Diagn Microbiol Infect Dis, 2021;101(1):115418","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"ref135","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11908-020-0710-9","article-title":"The Battle Is on: New Beta-Lactams for the Treatment of Multidrug-Resistant Gram-Negative Organisms","volume":"22","author":"Noval M, Banoub M, Claeys KC, Heil E","year":"2020","unstructured":"135. Noval M, Banoub M, Claeys KC, Heil E, The Battle Is on: New Beta-Lactams for the Treatment of Multidrug-Resistant Gram-Negative Organisms, Curr Infect Dis Rep, 2020;22(1):1","journal-title":"Curr Infect Dis Rep"},{"issue":"8","key":"ref136","doi-asserted-by":"publisher","first-page":"4856","DOI":"10.1128\/AAC.00843-15","article-title":"Activity of Meropenem Combined with RPX7009, a Novel \u03b2-Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City","volume":"59","author":"Lapuebla A, Abdallah M, Olafisoye O, Cortes C, Urban C, Quale J","year":"2015","unstructured":"136. Lapuebla A, Abdallah M, Olafisoye O, Cortes C, Urban C, Quale J, Activity of Meropenem Combined with RPX7009, a Novel \u03b2-Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City, Antimicrob Agents Chemother, 2015;59(8):4856-60","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"ref137","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1080\/14787210.2020.1756775","article-title":"Meropenem\/vaborbactam: a next generation \u03b2-lactam \u03b2-lactamase inhibitor combination","volume":"18","author":"Novelli A, Del Giacomo P, Rossolini GM, Tumbarello M","year":"2020","unstructured":"137. Novelli A, Del Giacomo P, Rossolini GM, Tumbarello M, Meropenem\/vaborbactam: a next generation \u03b2-lactam \u03b2-lactamase inhibitor combination, Expert Rev Anti Infect Ther, 2020;18(7):643-655","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"1","key":"ref138","doi-asserted-by":"publisher","first-page":"e01665","DOI":"10.1128\/AAC.01665-18","article-title":"Activity of Meropenem-Vaborbactam against Pseudomonas aeruginosa and Acinetobacter baumannii in a Neutropenic Mouse Thigh Infection Model","volume":"63","author":"Sabet M, Tarazi Z, Griffith DC","year":"2018","unstructured":"138. Sabet M, Tarazi Z, Griffith DC, Activity of Meropenem-Vaborbactam against Pseudomonas aeruginosa and Acinetobacter baumannii in a Neutropenic Mouse Thigh Infection Model, Antimicrob Agents Chemother, 2018;63(1):e01665-18","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"ref139","doi-asserted-by":"publisher","first-page":"e02177","DOI":"10.1128\/AAC.02177-19","article-title":"Activity of Meropenem-Vaborbactam against Bacterial Isolates Causing Pneumonia in Patients in U.S. Hospitals during 2014 to 2018","volume":"64","author":"Carvalhaes CG, Shortridge D, Sader HS, Castanheira M","year":"2020","unstructured":"139. Carvalhaes CG, Shortridge D, Sader HS, Castanheira M, Activity of Meropenem-Vaborbactam against Bacterial Isolates Causing Pneumonia in Patients in U.S. Hospitals during 2014 to 2018, Antimicrob Agents Chemother, 2020;64(3):e02177-19","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"ref140","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/medsci6010001","article-title":"Carbapenem Resistance: A Review","volume":"6","author":"Codjoe FS, Donkor ES","year":"2017","unstructured":"140. Codjoe FS, Donkor ES, Carbapenem Resistance: A Review, Med Sci (Basel), 2017;6(1):1","journal-title":"Med Sci (Basel)"},{"issue":"11","key":"ref141","doi-asserted-by":"publisher","first-page":"4943","DOI":"10.1128\/AAC.00296-11","article-title":"Carbapenems: past, present, and future","volume":"55","author":"Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA","year":"2011","unstructured":"141. Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA, Carbapenems: past, present, and future, Antimicrob Agents Chemother, 2011;55(11):4943-60","journal-title":"Antimicrob Agents Chemother"},{"key":"ref142","article-title":"Carbapenem-Resistant Enterobacterales","author":"Smith HZ, Hollingshead CM, Kendall B","year":"2024","unstructured":"142. Smith HZ, Hollingshead CM, Kendall B, Carbapenem-Resistant Enterobacterales, StatPearls [Internet], Treasure Island (FL):StatPearls Publishing, 2024;Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK551704","journal-title":"StatPearls [Internet]"},{"key":"ref143","article-title":"Healthcare-Associated Infections (HAIs): CRE Technical Information","author":"Centers for Disease Control and Prevention (CDC)","year":"2019","unstructured":"143. Centers for Disease Control and Prevention (CDC), Healthcare-Associated Infections (HAIs): CRE Technical Information, 2019;Available from: https:\/\/www.cdc.gov\/hai\/organisms\/cre\/technical-info.html"},{"issue":"2","key":"ref144","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3390\/antibiotics11020281","article-title":"Quantitative Risk Assessment for the Introduction of Carbapenem-Resistant Enterobacteriaceae (CPE) into Dutch Livestock Farms","volume":"11","author":"Dankittipong N, Fischer EAJ, Swanenburg M, Wagenaar JA, Stegeman AJ, de Vos CJ","year":"2022","unstructured":"144. Dankittipong N, Fischer EAJ, Swanenburg M, Wagenaar JA, Stegeman AJ, de Vos CJ, Quantitative Risk Assessment for the Introduction of Carbapenem-Resistant Enterobacteriaceae (CPE) into Dutch Livestock Farms, Antibiotics (Basel), 2022;11(2):281","journal-title":"Antibiotics (Basel)"},{"issue":"10","key":"ref145","doi-asserted-by":"publisher","first-page":"693","DOI":"10.3390\/antibiotics9100693","article-title":"Molecular Epidemiology of Carbapenemases in Enterobacteriales from Humans, Animals, Food and the Environment","volume":"9","author":"Taggar G, Attiq Rheman M, Boerlin P, Diarra MS","year":"2020","unstructured":"145. Taggar G, Attiq Rheman M, Boerlin P, Diarra MS, Molecular Epidemiology of Carbapenemases in Enterobacteriales from Humans, Animals, Food and the Environment, Antibiotics (Basel), 2020;9(10):693","journal-title":"Antibiotics (Basel)"},{"issue":"3","key":"ref146","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1128\/CMR.00001-07","article-title":"Carbapenemases: the versatile beta-lactamases","volume":"20","author":"Queenan AM, Bush K","year":"2007","unstructured":"146. Queenan AM, Bush K, Carbapenemases: the versatile beta-lactamases, Clin Microbiol Rev, 2007;20(3):440-58","journal-title":"Clin Microbiol Rev"},{"key":"ref147","doi-asserted-by":"publisher","first-page":"104588","DOI":"10.1016\/j.meegid.2020.104588","article-title":"Evolving trends of New Delhi Metallo-betalactamse (NDM) variants: A threat to antimicrobial resistance","volume":"86","author":"Farhat N, Khan AU","year":"2020","unstructured":"147. Farhat N, Khan AU, Evolving trends of New Delhi Metallo-betalactamse (NDM) variants: A threat to antimicrobial resistance, Infect Genet Evol, 2020;86104588","journal-title":"Infect Genet Evol"},{"issue":"10","key":"ref148","doi-asserted-by":"publisher","first-page":"e00397","DOI":"10.1128\/AAC.00397-20","article-title":"Metallo-\u03b2-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline","volume":"64","author":"Boyd SE, Livermore DM, Hooper DC, Hope WW","year":"2020","unstructured":"148. Boyd SE, Livermore DM, Hooper DC, Hope WW, Metallo-\u03b2-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline, Antimicrob Agents Chemother, 2020;64(10):e00397-20","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"ref149","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/nyas.14223","article-title":"Plasmid evolution in carbapenemase-producing Enterobacteriaceae: a review","volume":"1457","author":"Kopotsa K, Osei Sekyere J, Mbelle NM","year":"2019","unstructured":"149. Kopotsa K, Osei Sekyere J, Mbelle NM, Plasmid evolution in carbapenemase-producing Enterobacteriaceae: a review, Ann N Y Acad Sci, 2019;1457(1):61-91","journal-title":"Ann N Y Acad Sci"},{"issue":"8","key":"ref150","doi-asserted-by":"publisher","first-page":"e0021622","DOI":"10.1128\/aac.00216-22","article-title":"OXA-48-Like \u03b2-Lactamases: Global Epidemiology, Treatment Options, and Development Pipeline","volume":"66","author":"Boyd SE, Holmes A, Peck R, Livermore DM, Hope W","year":"2022","unstructured":"150. Boyd SE, Holmes A, Peck R, Livermore DM, Hope W, OXA-48-Like \u03b2-Lactamases: Global Epidemiology, Treatment Options, and Development Pipeline, Antimicrob Agents Chemother, 2022;66(8):e0021622","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"ref151","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2217\/fmb.14.135","article-title":"Carbapenemase-producing Gram-negative bacteria: current epidemics, antimicrobial susceptibility and treatment options","volume":"10","author":"Jean SS, Lee WS, Lam C, Hsu CW, Chen RJ, Hsueh PR","year":"2015","unstructured":"151. Jean SS, Lee WS, Lam C, Hsu CW, Chen RJ, Hsueh PR, Carbapenemase-producing Gram-negative bacteria: current epidemics, antimicrobial susceptibility and treatment options, Future Microbiol, 2015;10(3):407-25","journal-title":"Future Microbiol"},{"issue":"9","key":"ref152","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1099\/jmm.0.001052","article-title":"Synergistic in vitro activity between aztreonam and amoxicillin-clavulanate against Enterobacteriaceae-producing class B and\/or class D carbapenemases with or without extended-spectrum \u03b2-lactamases","volume":"68","author":"Ract P, Compain F, Robin F, Decre D, Gallah S, Podglajen I","year":"2019","unstructured":"152. Ract P, Compain F, Robin F, Decre D, Gallah S, Podglajen I, Synergistic in vitro activity between aztreonam and amoxicillin-clavulanate against Enterobacteriaceae-producing class B and\/or class D carbapenemases with or without extended-spectrum \u03b2-lactamases, J Med Microbiol, 2019;68(9):1292-1298","journal-title":"J Med Microbiol"},{"issue":"8","key":"ref153","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1007\/s10096-021-04197-3","article-title":"Ceftazidime-avibactam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-\u03b2-lactamase-producing Klebsiella pneumoniae","volume":"40","author":"Maraki S, Mavromanolaki VE, Moraitis P, Stafylaki D, Kasimati A, Magkafouraki E","year":"2021","unstructured":"153. Maraki S, Mavromanolaki VE, Moraitis P, Stafylaki D, Kasimati A, Magkafouraki E, Ceftazidime-avibactam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-\u03b2-lactamase-producing Klebsiella pneumoniae, Eur J Clin Microbiol Infect Dis, 2021;40(8):1755-1759","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"4","key":"ref154","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1093\/cid\/ciz1159","article-title":"Aztreonam Combination Therapy: An Answer to Metallo-\u03b2-Lactamase-Producing Gram-Negative Bacteria?","volume":"71","author":"Shields RK, Doi Y","year":"2020","unstructured":"154. Shields RK, Doi Y, Aztreonam Combination Therapy: An Answer to Metallo-\u03b2-Lactamase-Producing Gram-Negative Bacteria?, Clin Infect Dis, 2020;71(4):1099-1101","journal-title":"Clin Infect Dis"},{"issue":"9","key":"ref155","doi-asserted-by":"publisher","first-page":"e00472","DOI":"10.1128\/AAC.00472-17","article-title":"In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015","volume":"61","author":"Karlowsky JA, Kazmierczak KM, de Jonge BLM, Hackel MA, Sahm DF, Bradford PA","year":"2017","unstructured":"155. Karlowsky JA, Kazmierczak KM, de Jonge BLM, Hackel MA, Sahm DF, Bradford PA, In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015, Antimicrob Agents Chemother, 2017;61(9):e00472-17","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"ref156","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1093\/jac\/dkx496","article-title":"Clinical outcomes after combination treatment with ceftazidime\/avibactam and aztreonam for NDM-1\/OXA-48\/CTX-M-15-producing Klebsiella pneumoniae infection","volume":"73","author":"Shaw E, Rombauts A, Tubau F, Padull\u00e9s A, C\u00e0mara J, Lozano T","year":"2018","unstructured":"156. Shaw E, Rombauts A, Tubau F, Padull\u00e9s A, C\u00e0mara J, Lozano T, Clinical outcomes after combination treatment with ceftazidime\/avibactam and aztreonam for NDM-1\/OXA-48\/CTX-M-15-producing Klebsiella pneumoniae infection, J Antimicrob Chemother, 2018;73(4):1104-1106","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"ref157","doi-asserted-by":"publisher","first-page":"e169","DOI":"10.1093\/cid\/ciaa1478","article-title":"Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum \u03b2-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P.aeruginosa)","volume":"72","author":"Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ","year":"2021","unstructured":"157. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ, Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum \u03b2-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P.aeruginosa), Clin Infect Dis, 2021;72(7):e169-e183","journal-title":"Clin Infect Dis"},{"issue":"2","key":"ref158","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s40265-013-0013-7","article-title":"Ceftazidime-avibactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination","volume":"73","author":"Zhanel GG, Lawson CD, Adam H, Schweizer F, Zelenitsky S, Lagac\u00e9-Wiens PR","year":"2013","unstructured":"158. Zhanel GG, Lawson CD, Adam H, Schweizer F, Zelenitsky S, Lagac\u00e9-Wiens PR, Ceftazidime-avibactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination, Drugs, 2013;73(2):159-77","journal-title":"Drugs"},{"issue":"29","key":"ref159","doi-asserted-by":"publisher","first-page":"11663","DOI":"10.1073\/pnas.1205073109","article-title":"Avibactam is a covalent, reversible, non-\u03b2-lactam \u03b2-lactamase inhibitor","volume":"109","author":"Ehmann DE, Jahi\u0107 H, Ross PL, Gu RF, Hu J, Kern G","year":"2012","unstructured":"159. Ehmann DE, Jahi\u0107 H, Ross PL, Gu RF, Hu J, Kern G, Avibactam is a covalent, reversible, non-\u03b2-lactam \u03b2-lactamase inhibitor, Proc Natl Acad Sci U S A, 2012;109(29):11663-8","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"ref160","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1093\/jac\/dky295","article-title":"Effectiveness of ceftazidime\/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae","volume":"73","author":"Sousa A, P\u00e9rez-Rodr\u00edguez MT, Soto A, Rodr\u00edguez L, P\u00e9rez-Landeiro A, Mart\u00ednez-Lamas L","year":"2018","unstructured":"160. Sousa A, P\u00e9rez-Rodr\u00edguez MT, Soto A, Rodr\u00edguez L, P\u00e9rez-Landeiro A, Mart\u00ednez-Lamas L, Effectiveness of ceftazidime\/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae, J Antimicrob Chemother, 2018;73(11):3170-3175","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"ref161","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ijantimicag.2018.11.015","article-title":"Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam","volume":"53","author":"De la Calle C, Rodr\u00edguez O, Morata L, Marco F, Cardozo C, Garc\u00eda-Vidal C","year":"2019","unstructured":"161. De la Calle C, Rodr\u00edguez O, Morata L, Marco F, Cardozo C, Garc\u00eda-Vidal C, Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam, Int J Antimicrob Agents, 2019;53(4):520-524","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"ref162","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae","volume":"66","author":"van Duin D, Lok JJ, Earley M, Cober E, Richter SS, Perez F, Antibacterial Resistance Leadership Group","year":"2018","unstructured":"162. van Duin D, Lok JJ, Earley M, Cober E, Richter SS, Perez F, Antibacterial Resistance Leadership Group, Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae, Clin Infect Dis, 2018;66(2):163-171","journal-title":"Clin Infect Dis"},{"issue":"8","key":"ref163","doi-asserted-by":"publisher","first-page":"e00883","DOI":"10.1128\/AAC.00883-17","article-title":"Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia","volume":"61","author":"Shields RK, Nguyen MH, Chen L, Press EG, Potoski BA, Marini RV","year":"2017","unstructured":"163. Shields RK, Nguyen MH, Chen L, Press EG, Potoski BA, Marini RV, Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia, Antimicrob Agents Chemother, 2017;61(8):e00883-17","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"ref164","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1093\/cid\/ciab176","article-title":"Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study","volume":"73","author":"Tumbarello M, Raffaelli F, Giannella M, Mantengoli E, Mularoni A, Venditti M","year":"2021","unstructured":"164. Tumbarello M, Raffaelli F, Giannella M, Mantengoli E, Mularoni A, Venditti M, Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study, Clin Infect Dis, 2021;73(9):1664-1676","journal-title":"Clin Infect Dis"},{"issue":"2","key":"ref165","doi-asserted-by":"publisher","first-page":"ofaa651","DOI":"10.1093\/ofid\/ofaa651","article-title":"Meta-analysis of Clinical Outcomes Using Ceftazidime\/Avibactam, Ceftolozane\/Tazobactam, and Meropenem\/Vaborbactam for the Treatment of Multidrug-Resistant Gram-Negative Infections","volume":"8","author":"Wilson GM, Fitzpatrick M, Walding K, Gonzalez B, Schweizer ML, Suda KJ","year":"2021","unstructured":"165. Wilson GM, Fitzpatrick M, Walding K, Gonzalez B, Schweizer ML, Suda KJ, Meta-analysis of Clinical Outcomes Using Ceftazidime\/Avibactam, Ceftolozane\/Tazobactam, and Meropenem\/Vaborbactam for the Treatment of Multidrug-Resistant Gram-Negative Infections, Open Forum Infect Dis, 2021;8(2):ofaa651","journal-title":"Open Forum Infect Dis"},{"key":"ref166","article-title":"AVYCAZ safely and effectively","author":"United States Food and Drug Administration","unstructured":"166. United States Food and Drug Administration, AVYCAZ safely and effectively, Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/206494s005,s006lbl.pdf"},{"issue":"11","key":"ref167","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program","volume":"62","author":"Mazuski JE, Gasink LB, Armstrong J, Broadhurst H, Stone GG, Rank D","year":"2016","unstructured":"167. Mazuski JE, Gasink LB, Armstrong J, Broadhurst H, Stone GG, Rank D, Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program, Clin Infect Dis, 2016;62(11):1380-1389","journal-title":"Clin Infect Dis"},{"issue":"6","key":"ref168","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program","volume":"63","author":"Wagenlehner FM, Sobel JD, Newell P, Armstrong J, Huang X, Stone GG","year":"2016","unstructured":"168. Wagenlehner FM, Sobel JD, Newell P, Armstrong J, Huang X, Stone GG, Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program, Clin Infect Dis, 2016;63(6):754-762","journal-title":"Clin Infect Dis"},{"issue":"3","key":"ref169","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres A, Zhong N, Pachl J, Timsit JF, Kollef M, Chen Z","year":"2018","unstructured":"169. Torres A, Zhong N, Pachl J, Timsit JF, Kollef M, Chen Z, Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial, Lancet Infect Dis, 2018;18(3):285-295","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"ref170","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1128\/AAC.03042-15","article-title":"In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014)","volume":"60","author":"de Jonge BL, Karlowsky JA, Kazmierczak KM, Biedenbach DJ, Sahm DF, Nichols WW","year":"2016","unstructured":"170. de Jonge BL, Karlowsky JA, Kazmierczak KM, Biedenbach DJ, Sahm DF, Nichols WW, In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014), Antimicrob Agents Chemother, 2016;60(5):3163-9","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"ref171","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1093\/jac\/dkz456","article-title":"In vitro activity of ceftazidime\/avibactam against isolates of carbapenem-non-susceptible Enterobacteriaceae collected during the INFORM global surveillance programme (2015-17)","volume":"75","author":"Spiliopoulou I, Kazmierczak K, Stone GG","year":"2020","unstructured":"171. Spiliopoulou I, Kazmierczak K, Stone GG, In vitro activity of ceftazidime\/avibactam against isolates of carbapenem-non-susceptible Enterobacteriaceae collected during the INFORM global surveillance programme (2015-17), J Antimicrob Chemother, 2020;75(2):384-391","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"ref172","doi-asserted-by":"publisher","first-page":"e00989","DOI":"10.1128\/AAC.00989-17","article-title":"Resistance to Ceftazidime-Avibactam Is Due to Transposition of KPC in a Porin-Deficient Strain of Klebsiella pneumoniae with Increased Efflux Activity","volume":"61","author":"Nelson K, Hemarajata P, Sun D, Rubio-Aparicio D, Tsivkovski R, Yang S","year":"2017","unstructured":"172. Nelson K, Hemarajata P, Sun D, Rubio-Aparicio D, Tsivkovski R, Yang S, Resistance to Ceftazidime-Avibactam Is Due to Transposition of KPC in a Porin-Deficient Strain of Klebsiella pneumoniae with Increased Efflux Activity, Antimicrob Agents Chemother, 2017;61(10):e00989-17","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"ref173","doi-asserted-by":"publisher","first-page":"e00537","DOI":"10.1128\/AAC.00537-17","article-title":"Resistance to Ceftazidime-Avibactam in Klebsiella pneumoniae Due to Porin Mutations and the Increased Expression of KPC-3","volume":"61","author":"Humphries RM, Hemarajata P","year":"2017","unstructured":"173. Humphries RM, Hemarajata P, Resistance to Ceftazidime-Avibactam in Klebsiella pneumoniae Due to Porin Mutations and the Increased Expression of KPC-3, Antimicrob Agents Chemother, 2017;61(6):e00537-17","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"ref174","doi-asserted-by":"publisher","first-page":"6605","DOI":"10.1128\/AAC.01165-15","article-title":"First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate","volume":"59","author":"Humphries RM, Yang S, Hemarajata P, Ward KW, Hindler JA, Miller SA","year":"2015","unstructured":"174. Humphries RM, Yang S, Hemarajata P, Ward KW, Hindler JA, Miller SA, First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate, Antimicrob Agents Chemother, 2015;59(10):6605-7","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"ref175","doi-asserted-by":"publisher","first-page":"e2097","DOI":"10.1128\/AAC.02097-16","article-title":"Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections","volume":"61","author":"Shields RK, Chen L, Cheng S, Chavda KD, Press EG, Snyder A","year":"2017","unstructured":"175. Shields RK, Chen L, Cheng S, Chavda KD, Press EG, Snyder A, Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections, Antimicrob Agents Chemother, 2017;61(3):e2097-16","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"ref176","doi-asserted-by":"publisher","first-page":"e00321","DOI":"10.1128\/AAC.00321-20","article-title":"KPC-50 Confers Resistance to Ceftazidime-Avibactam Associated with Reduced Carbapenemase Activity","volume":"64","author":"Poirel L, Vuillemin X, Juhas M, Masseron A, Bechtel-Grosch U, Tiziani S","year":"2020","unstructured":"176. Poirel L, Vuillemin X, Juhas M, Masseron A, Bechtel-Grosch U, Tiziani S, KPC-50 Confers Resistance to Ceftazidime-Avibactam Associated with Reduced Carbapenemase Activity, Antimicrob Agents Chemother, 2020;64(8):e00321-20","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"ref177","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/emph\/eou024","article-title":"Antibiotic resistance management","volume":"2014","author":"Read AF, Woods RJ","year":"2014","unstructured":"177. Read AF, Woods RJ, Antibiotic resistance management, Evol Med Public Health, 2014;2014(1):147","journal-title":"Evol Med Public Health"},{"issue":"7440","key":"ref178","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/495141a","article-title":"The antibiotic alarm","volume":"495","year":"2013","unstructured":"178. The antibiotic alarm, Nature, 2013;495(7440):141","journal-title":"Nature"},{"key":"ref179","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3389\/fpubh.2014.00145","article-title":"The antimicrobial resistance crisis: causes, consequences, and management","volume":"2","author":"Michael CA, Dominey-Howes D, Labbate M","year":"2014","unstructured":"179. Michael CA, Dominey-Howes D, Labbate M, The antimicrobial resistance crisis: causes, consequences, and management, Front Public Health, 2014;2145","journal-title":"Front Public Health"},{"issue":"5","key":"ref180","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1186\/s13054-014-0480-6","article-title":"Antibiotic stewardship in the intensive care unit","volume":"18","author":"Luyt CE, Br\u00e9chot N, Trouillet JL, Chastre J","year":"2014","unstructured":"180. Luyt CE, Br\u00e9chot N, Trouillet JL, Chastre J, Antibiotic stewardship in the intensive care unit, Crit Care, 2014;18(5):480","journal-title":"Crit Care"},{"issue":"6","key":"ref181","first-page":"849","article-title":"Helicobacter pylori and peptic ulcer in cirrhotic patients","volume":"24","author":"Rahimkhani M, Ghofrani H","year":"2008","unstructured":"181. Rahimkhani M, Ghofrani H, Helicobacter pylori and peptic ulcer in cirrhotic patients, Pakistan Journal of Medical Sciences, 2008;24(6):849-852","journal-title":"Pakistan Journal of Medical Sciences"},{"issue":"4","key":"ref182","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1177\/003335491412900402","article-title":"Antibiotic resistance: a public health crisis","volume":"129","author":"Lushniak BD","year":"2014","unstructured":"182. Lushniak BD, Antibiotic resistance: a public health crisis, Public Health Rep, 2014;129(4):314-6","journal-title":"Public Health Rep"},{"issue":"1","key":"ref183","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4161\/gmic.28027","article-title":"Off-label abuse of antibiotics by bacteria","volume":"5","author":"Viswanathan VK","year":"2014","unstructured":"183. Viswanathan VK, Off-label abuse of antibiotics by bacteria, Gut Microbes, 2014;5(1):3-4","journal-title":"Gut Microbes"},{"key":"ref184","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.5958\/0974-360X.2017.00331.6","article-title":"Antibiotic resistance-reasons and the most common resistant pathogens-a review","volume":"10","author":"Sreeja MK, Gowrishankar NL, Adisha S, Divya KC","year":"2017","unstructured":"184. Sreeja MK, Gowrishankar NL, Adisha S, Divya KC, Antibiotic resistance-reasons and the most common resistant pathogens-a review, Res J Pharm Technol, 2017;101886-1890","journal-title":"Res J Pharm Technol"},{"issue":"4","key":"ref185","doi-asserted-by":"publisher","first-page":"795","DOI":"10.3390\/molecules23040795","article-title":"Antibiotic Use in Agriculture and Its Consequential Resistance in Environmental Sources: Potential Public Health Implications","volume":"23","author":"Manyi-Loh C, Mamphweli S, Meyer E, Okoh A","year":"2018","unstructured":"185. Manyi-Loh C, Mamphweli S, Meyer E, Okoh A, Antibiotic Use in Agriculture and Its Consequential Resistance in Environmental Sources: Potential Public Health Implications, Molecules, 2018;23(4):795","journal-title":"Molecules"},{"key":"ref186","doi-asserted-by":"publisher","first-page":"f1493","DOI":"10.1136\/bmj.f1493","article-title":"The true cost of antimicrobial resistance","volume":"346","author":"Smith R, Coast J","year":"2013","unstructured":"186. Smith R, Coast J, The true cost of antimicrobial resistance, BMJ, 2013;346f1493","journal-title":"BMJ"},{"issue":"11","key":"ref187","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1086\/507962","article-title":"Impact of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study","volume":"27","author":"Lee SY, Kotapati S, Kuti JL, Nightingale CH, Nicolau DP","year":"2006","unstructured":"187. Lee SY, Kotapati S, Kuti JL, Nightingale CH, Nicolau DP, Impact of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study, Infect Control Hosp Epidemiol, 2006;27(11):1226-32","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"6","key":"ref188","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1128\/JCM.01983-09","article-title":"Typhoid in Kenya is associated with a dominant multidrug-resistant Salmonella enterica serovar Typhi haplotype that is also widespread in Southeast Asia","volume":"48","author":"Kariuki S, Revathi G, Kiiru J, Mengo DM, Mwituria J, Muyodi J","year":"2010","unstructured":"188. Kariuki S, Revathi G, Kiiru J, Mengo DM, Mwituria J, Muyodi J, Typhoid in Kenya is associated with a dominant multidrug-resistant Salmonella enterica serovar Typhi haplotype that is also widespread in Southeast Asia, J Clin Microbiol, 2010;48(6):2171-6","journal-title":"J Clin Microbiol"},{"issue":"5","key":"ref189","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S1473-3099(11)70059-7","article-title":"Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study","volume":"11","author":"Walsh TR, Weeks J, Livermore DM, Toleman MA","year":"2011","unstructured":"189. Walsh TR, Weeks J, Livermore DM, Toleman MA, Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study, Lancet Infect Dis, 2011;11(5):355-62","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"ref190","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40273-014-0242-y","article-title":"Economic features of antibiotic resistance: the case of methicillin-resistant Staphylococcus aureus","volume":"33","author":"Antonanzas F, Lozano C, Torres C","year":"2015","unstructured":"190. Antonanzas F, Lozano C, Torres C, Economic features of antibiotic resistance: the case of methicillin-resistant Staphylococcus aureus, Pharmacoeconomics, 2015;33(4):285-325","journal-title":"Pharmacoeconomics"},{"key":"ref191","unstructured":"191. Linezolid price in Romania, Available from: https:\/\/comenzi.farmaciatei.ro\/medicamente-cu-reteta\/medicamente\/linezolid-600-mg-10-comprimate-filmate-krka-p356273","journal-title":"Linezolid price in Romania"},{"key":"ref192","article-title":"EU Action on Antimicrobial Resistance","author":"European Commission Public Health","unstructured":"192. European Commission Public Health, EU Action on Antimicrobial Resistance, Available from: https:\/\/ec.europa.eu\/health\/antimicrobial-resistance\/eu-action-antimicrobial-resistance_en"},{"key":"ref193","author":"University of Oxford New Resistance-Busting Antibiotic Combination Could Extend the Use of 'Last-Resort' Antibiotics","year":"2021","unstructured":"193. University of Oxford New Resistance-Busting Antibiotic Combination Could Extend the Use of 'Last-Resort' Antibiotics, 2021;Available from: https:\/\/www.ox.ac.uk\/news\/2021-12-14-new-resistance-busting-antibiotic-combination-could-extend-use-last-resort"}],"container-title":["Journal of Medicine and Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/medandlife.org\/all-issues\/2024\/issue-3-2024\/the-burden-of-antibiotic-resistance-of-the-main-microorganisms-causing-infections-in-humans-review-of-the-literature\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T06:13:48Z","timestamp":1724048028000},"score":1,"resource":{"primary":{"URL":"https:\/\/medandlife.org\/all-issues\/2024\/issue-3-2024\/the-burden-of-antibiotic-resistance-of-the-main-microorganisms-causing-infections-in-humans-review-of-the-literature\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":193,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["JMedLife-17-246"],"URL":"https:\/\/doi.org\/10.25122\/jml-2023-0404","relation":{},"ISSN":["1844-3117"],"issn-type":[{"value":"1844-3117","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]}}}